Adynxx (ADYX) 10-K 14 Mar 17 2016 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2016	Mar. 07, 2017	Jun. 30, 2016
Document Information [Line Items]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	FY
Entity Registrant Name	Alliqua BioMedical, Inc.
Entity Central Index Key	1,054,274
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Filer Category	Smaller Reporting Company
Entity Public Float			$ 27,314,605
Trading Symbol	ALQA
Entity Common Stock, Shares Outstanding		35,109,601

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Current Assets:
Cash and cash equivalents	$ 5,580	$ 26,080
Accounts receivable, net	2,760	2,060
Inventory, net	2,702	2,275
Prepaid expenses and other current assets	735	942
Current assets of discontinued operations	0	1,315
Total current assets	11,777	32,672
Improvements and equipment, net	2,092	1,847
Intangible assets, net	28,498	33,667
Goodwill, net	11,959	21,166
Other assets	173	173
Assets of discontinued operations - noncurrent	0	227
Total assets	54,499	89,752
Current Liabilities:
Accounts payable	2,612	2,594
Accrued expenses and other current liabilities	5,286	3,071
Contingent consideration, current	675	2,573
Senior secured term loan, net	11,541	0
Warrant liability	20	861
Current liabilities of discontinued operations	0	103
Total current liabilities	20,134	9,202
Senior secured term loan, net	0	12,126
Contingent consideration, long-term	1,141	14,455
Deferred tax liability	749	1,468
Other long-term liabilities	385	76
Total liabilities	22,409	37,327
Commitments and Contingencies
Stockholders' Equity
Preferred Stock, par value $0.001 per share, 1,000,000 shares authorized, no shares issued and outstanding	0	0
Common Stock, par value $0.001 per share, 95,000,000 shares authorized; 29,669,036 and 27,668,913 shares issued and outstanding as of December 31, 2016 and December 31, 2015, respectively	30	28
Additional paid-in capital	156,363	148,457
Accumulated deficit	(124,303)	(96,060)
Total stockholders' equity	32,090	52,425
Total liabilities and stockholders' equity	$ 54,499	$ 89,752

CONSOLIDATED BALANCE SHEETS _Pa

CONSOLIDATED BALANCE SHEETS [Parenthetical] - $ / shares	Dec. 31, 2016	Dec. 31, 2015
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	95,000,000	95,000,000
Common stock, shares issued	29,669,036	27,668,913
Common stock, shares outstanding	29,669,036	27,668,913

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Revenue, net of returns, allowances and discounts	$ 18,240,000	$ 12,177,000
Cost of revenues	6,655,000	5,227,000
Gross profit	11,585,000	6,950,000
Operating expenses
Selling, general and administrative	37,125,000	34,340,000
Research and product development	859,000	715,000
Milestone expense to licensor	1,000,000	0
Acquisition-related	2,959,000	2,876,000
Change in fair value of contingent consideration liability	(10,065,000)	(1,474,000)
Impairment charges	10,895,000	0
Total operating expenses	42,773,000	36,457,000
Loss from operations	(31,188,000)	(29,507,000)
Other (expense) income
Interest expense	(2,541,000)	(1,565,000)
Interest income	42,000	42,000
Change in fair value of warrant liability	841,000	2,095,000
Loss on early extinguishment of debt	(373,000)	0
Other income	100,000	0
Total other (expense) income	(1,931,000)	572,000
Loss from continuing operations before tax	(33,119,000)	(28,935,000)
Income tax benefit	715,000	1,718,000
Loss from continuing operations	(32,404,000)	(27,217,000)
Discontinued operations:
Income from discontinued operations, net of tax of $0 for the years ended December 31, 2016 and 2015	850,000	1,200,000
Gain on sale of assets, net of tax of $0 for the years ended December 31, 2016 and 2015	3,311,000	0
Income from discontinued operations, net of tax	4,161,000	1,200,000
Net loss	$ (28,243,000)	$ (26,017,000)
Net loss per basic and diluted common share:
Loss from continuing operations	$ (1.16)	$ (1.18)
Income from discontinued operations	0.03	0.05
Gain on sale of assets	0.12	0
Total from discontinued operations	0.15	0.05
Weighted average shares used in computing net income (loss) per common share:
Net loss per basic and diluted common share	$ (1.01)	$ (1.13)
Weighted average shares used in computing basic and diluted net loss per common share	27,965,626	23,061,931

CONSOLIDATED STATEMENTS OF OPE5

CONSOLIDATED STATEMENTS OF OPERATIONS [Parenthetical] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Discontinued Operation, Tax Effect of Income (Loss) from Discontinued Operation During Phase-out Period	$ 0	$ 0
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation	$ 0	$ 0

CONSOLIDATED STATEMENT OF STOCK

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands		Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]
Balance at Dec. 31, 2014		$ 22,511	$ 16	$ 92,538	$ (70,043)
Balance (in shares) at Dec. 31, 2014			16,202,689
Issuance of common stock in connection with the contingent consideration of the Celleration, Inc. acquisition (B)		15,207	$ 3	15,204	0
Issuance of common stock in connection with the contingent consideration of the Celleration, Inc. acquisition (B) (in shares)			3,168,229
Issuance of common stock for cash, net of issuance costs of $2,303,461		32,197	$ 8	32,189	0
Issuance of common stock for cash, net of issuance costs of $2,303,461 (in shares)			7,582,418
Exercise of common stock options		332	$ 0	332	0
Exercise of common stock options (in shares)			75,919
Cashless exercise of warrants		0	$ 0	0	0
Cashless exercise of warrants (in shares)			8,970
Extinguishment of warrant liability		31	$ 0	32	0
Stock-based compensation (A)		8,634	$ 1	8,633	0
Stock-based compensation (A) (in shares)			720,000
Net settlement on vesting of restricted stock awards		(471)	$ 0	(471)	0
Net settlement on vesting of restricted stock awards (in shares)			(89,312)
Net loss		(26,017)	$ 0	0	(26,017)
Balance at Dec. 31, 2015		52,425	$ 28	148,457	(96,060)
Balance (in shares) at Dec. 31, 2015			27,668,913
Issuance of common stock in connection with the contingent consideration of the Celleration, Inc. acquisition (B)	[1]	2,573	$ 1	2,572	0
Issuance of common stock in connection with the contingent consideration of the Celleration, Inc. acquisition (B) (in shares)	[1]		985,936
Extinguishment of warrant liability		0
Stock-based compensation (A)	[2]	5,337	$ 1	5,336	0
Stock-based compensation (A) (in shares)	[2]		1,016,527
Net settlement on vesting of restricted stock awards		(2)	$ 0	(2)	0
Warrant exchange (in shares)			(2,340)
Net loss		(28,243)	$ 0	0	(28,243)
Balance at Dec. 31, 2016		$ 32,090	$ 30	$ 156,363	$ (124,303)
Balance (in shares) at Dec. 31, 2016			29,669,036
[1]	Includes $2.6 million that was part of contingent consideration as of December 31, 2015, which was credited to equity upon the issuance of 985,936 common shares during the year ended December 31, 2016.
[2]	Includes $474,000 that was part of accrued expenses as of December 31, 2015, which was credited to equity upon the issuance of 324,561 restricted common shares during the year ended December 31, 2016.

CONSOLIDATED STATEMENT OF STOC7

CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY [Parenthetical] - USD ($)	12 Months Ended
	Dec. 31, 2016		Dec. 31, 2015
Accrued Liabilities			$ 474,000
Debt Conversion, Converted Instrument, Shares Issued	324,561
Payments of Stock Issuance Costs	$ 2,303,461
Business Combination, Contingent Consideration, Liability			$ 2,600,000
Common Stock [Member]
Stock Issued During Period, Shares, Acquisitions	985,936	[1]	3,168,229
[1]	Includes $2.6 million that was part of contingent consideration as of December 31, 2015, which was credited to equity upon the issuance of 985,936 common shares during the year ended December 31, 2016.

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Operating Activities
Net loss	$ (28,243)	$ (26,017)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,167	2,867
Amortization of deferred lease incentive	(42)	(8)
Lease incentive	267	0
Impairment charges	10,895	0
Deferred income tax benefit	(719)	(1,718)
Provision for doubtful accounts	38	108
Reserve for note receivable	1,020	0
Provision for excess and slow moving inventory	(58)	58
Stock-based compensation expense	4,863	8,634
Deferred rent	84	0
Accrued interest receivable	(19)	0
Amortization of debt issuance and debt discount costs	841	565
Loss on early extinguishment of debt	373	0
Change in fair value of warrant liability	(841)	(2,095)
Fair value adjustment of contingent consideration liability	(10,065)	(1,474)
Gain on sale of assets	(3,311)	0
Changes in operating assets and liabilities:
Accounts receivable	(281)	(780)
Inventory	(113)	(1,438)
Prepaid expenses and other assets	207	(257)
Accounts payable	(26)	572
Accrued expenses and other current liabilities	2,680	(639)
Net Cash Used in Operating Activities	(18,335)	(21,622)
Investing Activities
Proceeds from sale of assets	4,103	0
Purchase of improvements and equipment	(893)	(423)
Acquisition of business, net of cash acquired	0	(14,948)
Issuance of note	(1,000)	0
Net Cash Provided by (Used in) Investing Activities	2,210	(15,371)
Financing Activities
Contingent purchase price payments	(2,573)	0
Repayment of long-term debt	(1,748)	0
Prepayment penalty	(52)	0
Net proceeds from issuance of common stock	0	32,197
Net proceeds from long-term debt	0	14,244
Proceeds from the exercise of stock options	0	332
Payment of withholding taxes related to stock-based employee compensation	(2)	(471)
Net Cash (Used in) Provided by Financing Activities	(4,375)	46,302
Net (Decrease) Increase in Cash and Cash Equivalents	(20,500)	9,309
Cash and Cash Equivalents - Beginning of year	26,080	16,771
Cash and Cash Equivalents - End of year	5,580	26,080
Supplemental Disclosure of Cash Flows Information
Interest	1,599	1,000
Non-cash investing and financing activities:
Extinguishment of warrant liability due to cashless warrant exercise	0	31
2015 Accrued bonus awarded in equity	474	0
Common stock issued for contingent purchase price payments	2,573	0
Acquisition of business:
Current assets, excluding cash and cash equivalents	0	1,836
Intangibles	0	31,952
Goodwill	0	17,066	[1]
Liabilities assumed	0	(2,006)
Deferred tax liability	0	(3,122)
Contingent consideration	0	(15,570)
Issuance of common stock for acquisition	$ 0	$ (15,208)
[1]	Goodwill acquired as a result of the acquisition of Celleration in May 2015. See Note 5 – Acquisitions for further information on the acquisition.

Description of Business and Bas

Description of Business and Basis of Presentation	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Business Description and Basis of Presentation [Text Block]	1. Description of Business and Basis of Presentation Alliqua BioMedical, Inc. (the “Company”) is a regenerative technologies company that commercializes differentiated regenerative medical products which assist the body in the repair of human tissue. On October 5, 2016, the Company entered into a merger agreement to acquire the business of Soluble Systems, LLC (“Soluble”) through a series of transactions. On February 27, 2017, the Company terminated this agreement, due to its inability to secure the requisite financing to meet the closing conditions of the merger agreement. The merger agreement was contingent upon the Company securing debt or equity financing, or a combination thereof, that results in gross proceeds of at least $45 million, inclusive of any current indebtedness of Soluble or the Company that is assumed, restructured or refinanced by the combined company. Principles of Consolidation The accompanying consolidated financial statements include the financial statements of the Company and its wholly-owned subsidiaries, AquaMed Technologies, Inc., Alliqua Holdings, Inc. and Chesapeake Merger Corp. All significant inter-company transactions and accounts have been eliminated in consolidation. Certain amounts in prior periods have been reclassified to conform to the current year presentation. Such reclassifications did not have a material effect on the Company’s financial condition or results of operations as previously reported.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Significant Accounting Policies [Text Block]	2. Summary of Significant Accounting Policies The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates and assumptions include valuing equity securities and derivative financial instruments issued in financing transactions, allowance for doubtful accounts, inventory reserves, deferred taxes and related valuation allowances, and the fair values of long lived assets, intangibles, goodwill and contingent consideration. Actual results could differ from the estimates. Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. The Company’s balance of cash and cash equivalents at December 31, 2016 and 2015 consisted principally of bank deposits. From time to time, the Company’s cash account balances may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation guarantee limit. The Company reduces its exposure to credit risk by maintaining its cash deposits with major financial institutions and monitoring their credit ratings. Trade accounts receivable are stated at the amount the Company expects to collect and 213,000 175,000 Inventory is stated at the lower of cost, the value determined by the first-in, first-out method, or market. At each balance sheet date, the Company evaluates inventories for excess quantities, obsolescence or shelf life expiration. This evaluation includes analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, and a review of the shelf life expiration dates for products. To the extent that management determines there are excess or obsolete inventory or quantities with a shelf life that is too near its expiration for the Company to reasonably expect that it can sell those products prior to their expiration, the Company adjusts the carrying value to estimated net realizable value. Improvements and equipment are recorded at cost. Depreciation of equipment is computed utilizing the straight-line method over the estimated useful lives of the assets. Amortization of leasehold improvements is computed utilizing the straight-line method over the lesser of the lease term or the estimated useful life. Repairs and maintenance costs are expensed as incurred. The cost of major additions and improvements is capitalized, while maintenance and repair costs that do not improve or extend the lives of the respective assets are charged to operations as incurred. The Company records goodwill and other indefinite-lived assets in connection with business combinations. Goodwill, which represents the excess of acquisition cost over the fair value of the net tangible and intangible assets of acquired companies, is not amortized. Indefinite-lived assets are stated at fair value as of the date acquired in a business combination. The Company assesses the recoverability of goodwill and certain indefinite-lived intangible assets annually in the fourth quarter and between annual tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is done at a reporting unit level. Under Financial Accounting Standards Board (“FASB”) guidance for goodwill and intangible assets, a reporting unit is defined as an operating segment or one level below the operating segment, called a component. However, two or more components of an operating segment will be aggregated and deemed a single reporting unit if the components have similar economic characteristics. The Company operates as one reporting unit. Authoritative accounting guidance allows the Company to first assess qualitative factors to determine whether it is necessary to perform the more detailed two-step quantitative goodwill impairment test. The Company performs the quantitative test if its qualitative assessment determined it is more likely than not that a reporting unit’s fair value is less than its carrying amount. The Company may elect to bypass the qualitative assessment and proceed directly to the quantitative test for any reporting unit or asset. The quantitative goodwill impairment test, if necessary, is a two-step process. The first step is to identify the existence of a potential impairment by comparing the fair value of a reporting unit (the estimated fair value of a reporting unit is calculated using a discounted cash flow model) with its carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, the reporting unit’s goodwill is considered not to be impaired and performance of the second step of the quantitative goodwill impairment test is unnecessary. However, if the carrying amount of a reporting unit exceeds its fair value, the second step of the quantitative goodwill impairment test is performed to measure the amount of impairment loss to be recorded, if any. The second step of the quantitative goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds its implied fair value, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined using the same approach as employed when determining the amount of goodwill that would be recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of its assets and liabilities as if the reporting unit had been acquired in a business combination and the fair value was the purchase price paid to acquire the reporting unit. For the 2016 annual goodwill and certain indefinite-lived intangible assets impairment tests, the Company elected to bypass the qualitative assessment and proceeded directly to the quantitative analysis using a discounted cash flow method to estimate fair value. As a result of this test, the Company’s goodwill was determined to be impaired and an impairment charge of $ 9.2 1.7 10.9 At December 31, 2016 the remaining recorded goodwill was $ 12.0 21.2 Goodwill Balance as of December 31, 2014 $ 4,100 Goodwill acquired (1) 17,066 Balance as of December 31, 2015 $ 21,166 Impairment loss (9,207) Balance as of December 31, 2016 $ 11,959 (1) Goodwill acquired as a result of the acquisition of Celleration in May 2015. See Note 5 – Acquisitions . Long-Lived Assets Long-lived assets, such as property and equipment, and intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company’s long-lived intangible assets primarily consist of developed technology, customer lists/relationships, non-compete agreements, trade names and trademarks and are amortized ratably over a range of one to ten years which approximates customer attrition rate and technology obsolescence. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized of the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment is based on generally accepted valuation methodologies, as deemed appropriate. The factors used to determine fair value are subject to management’s judgement and expertise and include, but are not limited to, the present value of future cash flows, net of estimated operating costs, anticipated capital expenditures and various discount rates commensurate with the risk and current market conditions associated with realizing the expected cash flows projected. There were no long-lived asset impairment charges recorded during the years ended December 31, 2016 or 2015, other than the impairment of the MIST Therapy tradename during the year ended December 31, 2016 described above and in Note 10- Intangible Assets. The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows: Level 1: Observable prices in active markets for identical assets and liabilities. Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, title and risk of loss have passed to the customer, there is a fixed or determinable sales price, and collectability of that sales price is reasonably assured. The Company also recognizes revenue under a variety of rental programs of the MIST Therapy system, which is recognized over the term of the rental agreement. Costs associated with the production and procurement of product are included in cost of goods sold, including shipping and handling costs such as inbound freight costs, purchasing and receiving costs, inspection costs and other product procurement related charges. All other expenses are included in selling, general and administrative expenses, as the predominant expenses associated therewith are general and administrative in nature. Advertising costs are expensed as incurred and are included in selling, general and administrative expenses. Advertising expenses for the years ended December 31, 2016 and 2015 were approximately $ 2.4 2.1 Amounts billed to customers for shipping and handling are included in revenues. The related shipping and freight charges incurred by the Company are included in cost of goods sold and were not material for either the years ended December 31, 2016 or 2015. All research and product development costs are expensed as incurred. For the year ended December 31, 2016 and 2015, the Company incurred research and development costs of approximately $ 859,000 715,000 The Company accounts for income taxes pursuant to the asset and liability method which requires us to recognize current tax liabilities or receivables for the amount of taxes we estimate are payable or refundable for the current year and deferred tax assets and liabilities for the expected future tax consequences attributable to temporary differences between the financial statement carrying amounts and their respective tax bases of assets and liabilities and the expected benefits of net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period enacted. A valuation allowance is provided when it is more likely than not that a portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The Company adopted the provisions of Accounting Standards Codification Topic 740 (“ASC 740”) related to the accounting for uncertainty in income taxes recognized in an enterprise’s consolidated financial statements. ASC 740 prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. The benefit of tax positions taken or expected to be taken in the Company’s income tax returns are recognized in the financial statements if such positions are more likely than not of being sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits”. A liability is recognized (or amount of net operating loss carryover or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740. Interest costs and related penalties related to unrecognized tax benefits are required to be calculated, if applicable. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as selling, general and administrative expenses. No interest or penalties were recorded during the years ended December 31, 2016 and 2015. As of December 31, 2016 and December 31, 2015, no liability for unrecognized tax benefits was required to be reported. The Company does not expect any significant changes in its unrecognized tax benefits in the next year. The Company assesses classification of common stock purchase warrants at each reporting date to determine whether a change in classification between assets and liabilities or equity is required. The Company’s free standing derivatives consist of warrants to purchase common stock that were issued pursuant to a Securities Purchase Agreement on November 8, 2012 and pursuant to a Credit Agreement on May 29, 2015. The Company evaluated the common stock purchase warrants to assess their proper classification in the consolidated balance sheet and determined that the common stock purchase warrants contain exercise reset provisions. Accordingly, these instruments have been classified as warrant liabilities in the accompanying consolidated balance sheets as of December 31, 2016 and 2015. The Company re-measures warrant liabilities at each reporting and exercise date, with changes in fair value recognized in earnings for each reporting period. The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on interim financial reporting dates and vesting dates until the service period is complete. The fair value amount is then recognized over the period services are required to be provided in exchange for the award, usually the vesting period. The Company recognizes stock-based compensation expense on a graded-vesting basis over the requisite service period for each separately vesting tranche of each award. Stock-based compensation expense is reflected within cost of revenues and operating expenses in the consolidated statements of operations. The Company recognizes stock-based compensation expense for awards with performance conditions if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjusts stock-based compensation expense based on its probability assessment. In January 2017, the FASB issued Accounting Standards Update (ASU) 2017-04: “Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”), which removes Step 2 from the goodwill impairment test. It is effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment test performed with a measurement date after January 1, 2017. The Company does not expect this new guidance to have a material impact on its financial positions or results of operations. In January 2017, the FASB issued ASU 2017-01 “Business Combinations (Topic 805): Clarifying the Definition of a Business”, which clarifies the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The standard introduces a screen for determining when assets acquired are not a business and clarifies that a business must include, at a minimum, an input and a substantive process that contribute to an output to be considered a business. This standard is effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. The Company does not expect this new guidance to have a material impact on its financial position, results of operations or financial statement disclosures. In December 2016, the FASB issued ASU 2016-18 “Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force,” which clarifies the presentation requirements of restricted cash within the statement of cash flows. The changes in restricted cash and restricted cash equivalents during the period should be included in the beginning and ending cash and cash equivalents balance reconciliation on the statement of cash flows. When cash, cash equivalents, restricted cash or restricted cash equivalents are presented in more than one line item within the statement of financial position, an entity shall calculate a total cash amount in a narrative or tabular format that agrees to the amount shown on the statement of cash flows. Details on the nature and amounts of restricted cash should also be disclosed. This standard is effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. The Company does not expect this new guidance to have a material impact on its financial position or results of operations. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments.” ASU No. 2016-15 clarifies and provides specific guidance on eight cash flow classification issues that are not currently addressed by current GAAP and thereby reduce the current diversity in practice. ASU No. 2016-15 is effective for public business entities for annual periods, including interim periods within those annual periods, beginning after December 15, 2017, with early application permitted. This guidance is applicable to the Company’s fiscal year beginning January 1, 2018. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, which for the Company will commence with the year beginning January 1, 2018, with early adoption permitted commencing January 1, 2017. The Company is currently evaluating the standard to determine the impact of its adoption on the consolidated financial statements. In February 2016, the FASB issued Accounting Standards Update 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The standard requires a lessee to recognize assets and liabilities on the balance sheet for leases with lease terms greater than 12 months. The standard is effective for annual reporting periods beginning after December 15, 2018, which for the Company will commence with the year beginning January 1, 2019, with early application permitted. The adoption will require a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest period presented. The Company is currently evaluating the standard to determine the impact of the adoption on the consolidated financial statements. In November 2015, the FASB issued Accounting Standards Update 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-07”), an update to accounting guidance to simplify the presentation of deferred income taxes. The guidance requires an entity to classify all deferred tax liabilities and assets, along with any valuation allowance, as noncurrent in the balance sheet. The guidance is effective for public companies with annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is permitted. The Company has elected to early adopt ASU 2015-17 during the year ended December 31, 2015 with retrospective application. The adoption of ASU 2015-17 did not have a material impact on the Company’s consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. For all entities, the ASU is effective for annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted. The Company adopted this standard for the year ended December 31, 2016. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC Topic 605, “Revenue Recognition” and some cost guidance included in ASC Subtopic 605-35, “Revenue Recognition - Construction-Type and Production-Type Contracts.” The core principle of ASU 2014-09 is that revenue is recognized when the transfer of goods or services to customers occurs in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASU 2014-09 requires the disclosure of sufficient information to enable readers of the Company’s financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. ASU 2014-09 also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 provides two methods of retrospective application. The first method would require the Company to apply ASU 2014-09 to each prior reporting period presented. The second method would require the Company to retrospectively apply ASU 2014-09 with the cumulative effect recognized at the date of initial application. ASU 2014-09 will be effective for the Company beginning in fiscal 2019 as a result of ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” which was issued by the FASB in August 2015 and extended the original effective date by one year. The Company is currently evaluating the impact of adopting the available methodologies of ASU 2014-09 and 2015-14 upon its financial statements in future reporting periods. The Company has not yet selected a transition method. The Company is in the process of evaluating the new standard against its existing accounting policies, including the timing of revenue recognition, and its contracts with customers to determine the effect the guidance will have on its financial statements and what changes to systems and controls may be warranted. There have been four new ASUs issued amending certain aspects of ASU 2014-09, ASU 2016-08, “Principal versus Agent Considerations (Reporting Revenue Gross Versus Net),” was issued in March, 2016 to clarify certain aspects of the principal versus agent guidance in ASU 2014-09. In addition, ASU 2016-10, “Identifying Performance Obligations and Licensing,” issued in April 2016, amends other sections of ASU 2014-09 including clarifying guidance related to identifying performance obligations and licensing implementation. ASU 2016-12, “Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients” provides amendments and practical expedients to the guidance in ASU 2014-09 in the areas of assessing collectability, presentation of sales taxes received from customers, noncash consideration, contract modification and clarification of using the full retrospective approach to adopt ASU 2014-09. Finally, ASU 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,” was issued in December 2016, and provides elections regarding the disclosures required for remaining performance obligations in certain cases and also makes other technical corrections and improvements to the standard. With its evaluation of the impact of ASU 2014-09, the Company will also consider the impact on its financial statements related to the updated guidance provided by these four new ASUs.

Going Concern

Going Concern	12 Months Ended
	Dec. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Substantial Doubt about Going Concern [Text Block]	3 . Going Concern The Company’s financial statements are prepared using accounting principles generally accepted in the United States of America applicable to a going concern that contemplates the realization of assets and liquidation of liabilities in the normal course of business. As of December 31, 2016, the Company had a cash balance of $ 5.6 28.2 18.3 124.3 22,250 24,600 40.5 Management is evaluating all options to raise sufficient funds to meet to refinance its outstanding indebtedness and to fund the Company’s working capital requirements through debt and/or equity offerings. There can be no assurances, however, that management will be able to obtain sufficient additional funds when needed, or that such funds, if available, will be obtained on terms satisfactory to the Company. There is no assurance that the Company will be successful in achieving profitable operations. The consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded assets and liabilities that might be necessary should the Company be unable to continue as a going concern.

Net Loss Per Common Share

Net Loss Per Common Share	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	4. Net Loss Per Common Share Basic loss per share data for each period presented is computed using the weighted-average number of shares of common stock outstanding during each such period. Diluted income (loss) per share data is computed using the weighted-average number of common and dilutive common-equivalent shares outstanding during each period. Dilutive common-equivalent shares consist of: (a) shares that would be issued upon the exercise of stock options and warrants, computed using the treasury stock method; and (b) shares of non-vested restricted stock. The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: As of December 31, 2016 2015 Stock options 7,199,286 6,230,549 Warrants 3,365,407 3,372,550 Non-vested restricted stock 1,470,228 691,725 Total 12,034,921 10,294,824

Acquisitions

Acquisitions	12 Months Ended
	Dec. 31, 2016
Business Combinations [Abstract]
Business Combination Disclosure [Text Block]	5. Acquisitions Acquisition of Celleration, Inc. On May 29, 2015, the Company acquired all outstanding equity interest of Celleration, Inc. (“Celleration”), a medical device company focused on developing and commercializing the MIST Therapy® therapeutic ultrasound platform for the treatment of acute and chronic wounds for an aggregate purchase price of approximately $ 46.3 15.5 0.3 3,168,229 15.6 Services. Consideration: Common stock $ 15,208 Cash paid 15,476 Fair value of contingent consideration 15,570 Total consideration 46,254 Cash 528 Trade receivables 877 Inventory 341 Other current assets 207 Improvements and equipment 411 Tradenames 3,601 Technology 27,143 Customer relationships 1,208 Goodwill 17,066 Accounts payable (308) Accrued expenses and other liabilities (1,698) Deferred tax liability (3,122) Net assets acquired $ 46,254 The Company agreed to pay contingent consideration of 3.5 The first installment consisted of $ 2.6 986,000 2.6 10.2 8.7 As of December 31, 2016, the Company has recorded a liability of approximately $ 1.4 9.5 3.5 At the date of acquisition and December 31, 2016, the cash flow projection was discounted using a weighted average cost of capital of 12.5 Pro Forma Results The following unaudited pro forma financial information summarizes the results of operations for the year ended December 31, 2015, as if the acquisition had been completed as of January 1, 2015. The pro forma results were calculated applying the Company’s accounting policies and include the effects of adjustments related to the amortization charges from the acquired intangibles and long-term debt. The unaudited pro forma information does not purport to be indicative of the results that would have been obtained if the acquisitions had occurred at the beginning of the year prior to acquisition, nor of the results that may be reported in the future. Year Ended December 31, 2015 Revenues $ 16,266 Net loss $ (31,877) Net loss per share $ (1.31)

Discontinued Operations

Discontinued Operations	12 Months Ended
	Dec. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Disposal Groups, Including Discontinued Operations, Disclosure [Text Block]	6. Discontinued Operations Asset Sale In order to add capital and to focus on future investments on commercializing its own regenerative technologies effective June 30, 2016, the Company entered into a purchase agreement (the “Purchase Agreement”) with BSN medical, Inc. (“BSN”) whereby the Company agreed to sell to BSN (i) all of the Company’s rights, including all distribution rights, exclusivity rights, intellectual property rights and marketing rights (collectively, the “Rights”) to the sorbion product line pursuant to its distribution agreement (as amended, the “Sorbion Agreement”) with Sorbion GmbH & Co KG and (ii) the unsold inventory of sorbion products previously purchased by the Company in existence as of the closing, which occurred upon execution and delivery of the Purchase Agreement. In consideration for the sale of the Rights and the unsold inventory to BSN by the Company, BSN agreed to pay (i) $ 3.5 900,000 3.3 0 Proceeds from sale Consideration for inventory $ 603 Consideration for intangible assets 3,500 Total Consideration 4,103 Less: Net book value of assets sold to BSN Inventory, net (603) Intangibles, net (189) Total net book value of assets (792) Gain on sale of assets $ 3,311 On June 30, 2016, the Company entered into a ninety-day transition services agreement with BSN (“Transition Agreement”). Under the Transition Agreement, the Company was required to perform certain services related to the communication with distributors, wholesalers and customers in respect of transition of the business to BSN, as specified in the Transition Agreement. As compensation, BSN paid the Company $ 100,000 Discontinued Operations Years Ended December 31, 2016 2015 Revenue, net of returns, allowances and discounts $ 1,709 $ 2,864 Cost of revenues 536 823 Gross profit 1,173 2,041 Selling, general and administrative 323 841 Income from discontinued operations, net of tax $ 850 $ 1,200 Non-cash amortization expense of $ 38,000 76,000 There were no assets and liabilities of discontinued operations as of December 31, 2016. December 31, 2015 Accounts receivable, net $ 457 Inventory, net 858 Total current assets 1,315 Intangible assets, net 227 Total assets 1,542 Accounts payable 44 Accrued expenses and other current liabilities 59 Total current liabilities $ 103

Note Receivable

Note Receivable	12 Months Ended
	Dec. 31, 2016
Receivables [Abstract]
Financing Receivables [Text Block]	7. Note Receivable On August 25, 2016, in connection with the definitive agreement to acquire the business of Soluble Systems, LLC (“Soluble”), the Company provided Soluble with a $ 500,000 1.0 500,000 6 0

Inventory

Inventory	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	8. Inventory December 31, December 31, 2016 2015 Raw materials $ 135 $ 241 Work in process 173 228 Finished goods 2,394 1,865 Less: Inventory reserve for excess and slow moving inventory - (59) Total $ 2,702 $ 2,275

Improvements and Equipment, net

Improvements and Equipment, net	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	9. Improvements and Equipment, net December 31, Useful Life 2016 2015 (Years) Machinery and equipment 3-10 $ 5,041 $ 3,621 Office furniture and equipment 3-10 337 88 Leasehold improvements (A) 595 253 5,973 3,962 Less: Accumulated depreciation and amortization (3,881) (2,115) Improvements and equipment, net $ 2,092 $ 1,847 (A) Leasehold improvements are amortized over the shorter of the remaining lease term or estimated useful life. Depreciation and amortization expense was $ 1.8 421,000

Intangible Assets

Intangible Assets	12 Months Ended
	Dec. 31, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets Disclosure [Text Block]	10. Intangible Assets December 31, 2016 Useful Life Gross Accumulated Net Carrying (Years) Amount Amortization Impairment Amount Technology 10 $ 32,539 $ (7,312) $ - $ 25,227 Customer relationships 9-12 1,984 (639) - 1,345 Tradename 3 111 (98) - 13 Tradename related to MIST Therapy (1) 3 3,601 - (1,688) 1,913 Non-compete 1 208 (208) - - Total intangible assets 38,443 (8,257) (1,688) 28,498 December 31, 2015 Useful Life Gross Accumulated Net Carrying (Years) Amount Amortization Impairment Amount Intangible assets subject to amortization: Technology 10 $ 32,539 $ (4,057) $ - $ 28,482 Customer relationships 9-12 1,984 (449) - 1,535 Tradename 3 111 (62) - 49 Non-compete 1 208 (208) - - $ 34,842 $ (4,776) $ - $ 30,066 Indefinite-lived intangible assets: Tradename related to MIST Therapy (1) Indefinite 3,601 - - 3,601 Total indefinite-lived intangible assets 3,601 - - 3,601 Total intangible assets $ 38,443 $ (4,776) $ - $ 33,667 (1) In December 2016, the Company determined the tradename related to MIST Therapy was no longer an indefinite-lived intangible asset. The Company assigned a remaining useful of approximately 1.5 The Company performs its assessment of the recoverability of indefinite-lived intangible assets annually during the fourth quarter, or more frequently as impairment indicators arise, and it is based upon a comparison of the carrying value of such assets to their estimated fair values. The Company performed its most recent annual assessment during the four quarter of 2016, which resulted in an impairment charge of approximately $ 1.7 Amortization expense attributable to intangible assets for the year ended December 31, 2016 and 2015 was approximately $ 3.5 2.4 Expected Amortization Expense 2017 $ 4,807 2018 4,007 2019 3,169 2020 3,144 2021 3,098 Thereafter 10,273 Total $ 28,498

Accrued Expenses

Accrued Expenses	12 Months Ended
	Dec. 31, 2016
Accrued Liabilities, Current [Abstract]
Accounts Payable and Accrued Liabilities Disclosure [Text Block]	11. Accrued Expenses December 31, December 31, 2016 2015 Salaries, benefits and incentive compensation $ 3,070 $ 2,118 Milestone payment to licensor 1,000 - Professional fees 692 671 Royalty fees 197 52 Deferred revenue 181 92 Other 146 138 Total accrued expenses and other current liabilities $ 5,286 $ 3,071

Operating Leases

Operating Leases	12 Months Ended
	Dec. 31, 2016
Leases, Operating [Abstract]
Leases of Lessee Disclosure [Text Block]	12. Operating Leases The Company leases two corporate offices and one commercial manufacturing facility through operating lease agreements. The Company has obligations through 2023 for both corporate offices, one located in Eden Prairie, Minnesota, and one located in Yardley, Pennsylvania. The Company also has an obligation for its commercial manufacturing facility located in Langhorne, Pennsylvania, through 2026. During the year ended December 31, 2016, the landlord of the office in Yardley, Pennsylvania, made certain improvements to the facility. The Company recorded a deferred lease incentive liability of $ 267,000 2017 $ 500 2018 506 2019 512 2020 519 2021 525 Thereafter 1,311 Total $ 3,873 Total rent expense was $ 542,000 282,000

Debt

Debt	12 Months Ended
	Dec. 31, 2016
Debt Instruments [Abstract]
Long-term Debt [Text Block]	13. Debt Senior Secured Term Loan Facility On May 29, 2015, the Company entered into a Credit Agreement and Guaranty (the “Credit Agreement”) with Perceptive Credit Opportunities Fund, L.P. (“Perceptive”). The Credit Agreement provided a senior secured term loan in a single borrowing to the Company in the principal amount of $ 15.5 10.75 In connection with the Credit Agreement, the Company incurred approximately $ 1.3 273,000 169,000 In connection with the entry into the Credit Agreement, a five-year warrant (the “Warrant”) to purchase 750,000 0.001 5.5138 2.7 569,000 397,000 – Fair Value Measurement As of December 31, 2016, the Company was in default of a covenant pertaining to trailing twelve-month revenue under the Credit Agreement as a result of the Company’s failure to achieve approximately $ 22.3 24 13.8 In connection with the entry into the January 26, 2017 forbearance agreement, as amended March 7, 2017, we also amended and restated the warrant issued to Perceptive in connection with the closing of the Credit Agreement on May 29, 2015. The amended and restated warrant is exercisable for 2,000,000 0.50 Extinguishments On June 30, 2016, the Company entered into a Consent Under Credit Agreement (the “Consent Agreement”) with Perceptive pursuant to which Perceptive consented to the Purchase Agreement with BSN (see Note 6 – Discontinued Operations 1.8 1.7 52,000 373,000 52,000 226,000 95,000 December 31, December 31, 2016 2015 Long-term debt $ 13,752 $ 15,500 Unamortized debt issuance and discount costs (2,211) (3,374) Total $ 11,541 $ 12,126

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	14. Commitments and Contingencies License Agreement On July 15, 2011, the Company entered into a license agreement with Noble Fiber Technologies, LLC, whereby the Company has the exclusive right and license to manufacture and distribute “SilverSeal Hydrogel Wound Dressings” and “SilverSeal Hydrocolloid Wound Dressings”. The license is granted for ten years with an option to be extended for consecutive renewal periods of two years after the initial term. Royalties are to be paid equal to 9.75 600,000 600,000 500,000 598,000 497,000 Agreements for Human Placental Based Products Human Longevity, Inc. In November 2013, the Company entered into a License, Marketing and Development Agreement (the “License Agreement”) and Supply Agreement (the “Biovance Supply Agreement”) with Celgene Cellular Therapeutics (“CCT”), an affiliate of Celgene Corporation (“Celgene”). The agreements grant the Company an exclusive, royalty-bearing license in CCT’s intellectual property for certain placental based products, including ECM and Biovance ®, as well as provide the Company with the its requirements of Biovance for distribution. In January 2016, Human Longevity, Inc.’s (“HLI”), a genomics-based, technology-driven company, announced the purchase of LifebankUSA and other select assets from CCT. CCT assigned and HLI assumed the license and supply agreements the Company entered into with CCT, for certain placental based products. The Company is required to pay HLI annual license fees, designated amounts when certain milestone events occur and royalties on all sales of licensed products, with such amounts being variable and contingent on various factors. During the years ended December 31, 2016 and 2015, the Company incurred royalties of approximately $ 493,000 229,000 197,000 52,000 The License Agreement with HLI is terminable on a product-by-product basis if the Company fails to meet certain minimum sales thresholds in the second year or any subsequent year of commercial sales of each licensed product. Each year of commercial sales are referred to in the License Agreement as “launch years” and the calendar period constituting each launch year for each licensed product is determined in accordance with the terms of the License Agreement. To maintain its license for Biovance, the Company must meet a minimum gross sales amount for Biovance in the second year and third year of commercial sales. If the Company fails to meet the minimum threshold in the second year of commercial sales of product, it would be able to cure such failure by making a cure payment specified in the License Agreement to HLI; provided, however, the Company does not have the option to make a cure payment, should it fail to meet the minimum threshold for such product in the third year of commercial sales and HLI may terminate the License Agreement with respect to such product. In September 2014, the Company entered into a First Amendment to the License Agreement (the “Amended License Agreement”), pursuant to which the Company received the right to market Biovance for podiatric and orthopedic applications. The Amended License Agreement also amends certain terms and the related schedule for milestone payments to CCT. In May 2015, the Company amended its exclusive licensing agreement with CCT, which granted the Company the right to develop and market CCT’s connective tissue matrix product, also known as Interfyl. In April 2016, the Company entered into a Supply Agreement with HLI, pursuant to which HLI supplies the Company with the Company’s entire requirement of Interfyl™ Human Connective Tissue Matrix. Additionally, the Company agreed to make certain future milestone payments upon the achievement of certain milestones. The Company initiated sales and marketing efforts of Interfyl™ Human Connective Tissue Matrix in September 2016 and achieved two milestones under the license agreement. The Company is required to pay HLI $ 500,000 500,000 1.0 Litigation, Claims and Assessments The Company is subject to periodic lawsuits, investigations and claims that arise in the ordinary course of business. The Company is not party to any material litigation as of December 31, 2016.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2016
Stockholders Equity Note [Abstract]
Stockholders Equity Note Disclosure [Text Block]	15. Stockholders’ Equity Preferred Stock The Company has authorized 1,000,000 0.001 Common Stock On May 4, 2015, the Company closed an underwritten public offering of 7,582,418 4.55 32.2 On May 6, 2016, the Company held its 2016 annual meeting of stockholders. The stockholders approved an amendment to the Company’s Certificate of Incorporation to increase the number of authorized shares of common stock from 45,714,286 95,000,000 2011 Plan The Company maintains the 2011 Long-Term Incentive Plan (the “2011 Plan”) that provides for the granting of stock options, restricted stock units (“RSUs”), restricted stock and other awards to employees, directors and others. A total of 1,828,571 214,617 2014 Plan The Company maintains the 2014 Long-Term Incentive Plan (the “2014 Plan”) that provides for the granting of stock options, RSUs, restricted stock and other awards to employees, directors and others. On February 26, 2015 and May 6, 2015, the Company’s Board of Directors and the Company’s shareholders, respectively, approved an amendment to the 2014 Plan to increase the total number of shares of common stock authorized for issuance under the 2014 Plan by an additional 3,500,000 5,500,000 609,856 Stock-Based Compensation For the year ended December 31, 2016, the Company recognized $ 4.9 0.2 4.7 8.6 0.3 8.3 3.1 1.3 Restricted Stock Issuance Grantee Shares Vesting Grant Date Date Type Issued Term Value 02/06/15 Employee 600 [1] $ 3,738 06/15/15 Employee 120 [2] 630 2015 - Restricted Stock - Total 720 $ 4,368 02/09/16 Employee 325 [3] $ 474 05/11/16 Employee 700 [4] 602 2016 - Restricted Stock - Total 1,025 $ 1,076 [1] Vests in three equal annual installments, with one-third vesting on each of February 6, 2016, February 6, 2017 and February 6, 2018. [2] Vests in equal quarterly installments, with one-fourth vesting immediately and the remaining vesting equally over the next 3 years on the anniversaries of the date of grant. [3] Vests on the earlier of (a) the first anniversary of the date of grant or (b) the participant’s termination of service by the Company without cause. [4] Vests pursuant to the satisfaction of certain performance conditions. Weighted Average Grant Date Total Grant Number of Fair Value Per Date Fair Shares Share Value Non-vested, December 31, 2014 188 $ 7.03 $ 1,322 Granted 720 6.07 4,368 Vested (216) 6.76 (1,464) Forfeited - - - Non-vested, December 31, 2015 692 $ 6.11 $ 4,226 Granted 1,025 1.05 1,076 Vested (238) 6.00 (1,428) Forfeited (8) 1.46 (12) Non-vested, December 31, 2016 1,471 $ 2.43 $ 3,862 Warrants See Note 13 - Debt – Senior Secured Term Loan Facility During the year ended December 31, 2015, the Company issued an aggregate of 8,970 15,999 9,142 2.19 45,000 Fair Value Measurement There were no compensatory warrants issued during the years ended December 31, 2016 and 2015. Weighted Weighted Average Average Remaining Number of Exercise Life in Intrinsic Warrants Price per Warrant Years Value Outstanding, December 31, 2014 2,675 $ 5.76 Issued 750 5.51 Exercised (16) 2.19 Cancelled (36) 7.88 Outstanding, December 31, 2015 3,373 $ 5.70 Issued - - Exercised - - Cancelled (7) 8.75 Outstanding, December 31, 2016 3,366 $ 5.69 2.1 $ - Exercisable, December 31, 2016 3,366 $ 5.69 2.1 $ - Warrants Outstanding Warrants Exercisable Weighted Average Outstanding Remaining Exercisable Number of Life in Number of Exercise Price Warrants Years Warrants $2.19-$2.99 93 0.8 93 $3.00-$3.99 77 0.1 77 $4.00-$4.99 977 1.5 977 $5.00-$5.99 1,791 2.5 1,791 $6.00-$10.50 428 2.3 428 3,366 2.1 3,366 As of December 31, 2016 and 2015, warrants to purchase an aggregate of 816,287 shares of common stock at a weighted average exercise price of $5.24 per share were deemed to be a derivative liability. See Note 19 – Fair Value Measurement Stock Options Options – 2015 Grants During 2015, ten-year options to purchase an aggregate of 1,905,000 shares of common stock at exercise prices ranging from $2.38 to $6.23 with an aggregate grant date value of $8.0 million were granted to employees and directors. Options to purchase an aggregate of 1,818,000 and 87,000 shares of common stock were granted pursuant to the 2014 Plan and 2011 Plan, respectively. The options vest as follows: (i) options to purchase 4,500 shares vested immediately, (ii) options to purchase 90,000 shares vest one-twelfth monthly over one year, and (iii) options to purchase 1,810,500 shares vest ratably over three years on the anniversaries of the grant date. The grant date value is being amortized over the vesting term. Details of the grants with the more significant grant date values are as follows: (1) On February 6, 2015, ten-year options to purchase an aggregate of 745,000 shares of common stock with a grant date value of $3.6 million were granted to employees and an executive of the Company. The options are scheduled to vest and become exercisable at $6.23 per share ratably over three years on the anniversaries of the date of grant. (2) On May 29, 2015, ten-year options to purchase an aggregate of 455,000 shares of common stock with a grant date value of $1.8 million were granted to employees and a director of the Company. The options are scheduled to vest and become exercisable at $4.95 per share as follows: (i) options to purchase an aggregate of 440,000 shares of common stock vest ratably over three years on the anniversaries of the date of grant and (ii) an option to purchase 15,000 shares of common stock vests ratably over the next year on the monthly anniversary of the date of grant. (3) On August 3, 2015, ten-year options to purchase an aggregate of 270,000 shares of common stock with a grant date value of $1.0 million were granted to employees of the Company. The options are scheduled to vest and become exercisable at $5.08 per share ratably over three years on the anniversaries of the date of grant. Options – 2016 Grants During 2016, ten-year options to purchase an aggregate of 1,649,000 shares of common stock at exercise prices ranging from $ 0.80 2.20 1.3 shares vest one-twelfth monthly over one year, and (ii) options to purchase 1,424,000 shares vest ratably over three years on the anniversaries of the grant date. The grant date value is being amortized over the vesting term. Options – Summary Data Year Ended December 31, 2016 2015 Risk free interest rate 1.14%-2.06% 1.19% - 2.11% Expected term (years) 5.04-6.50 5.00-6.50 Expected volatility 89.53% - 89.95% 93.70% - 98.25% Expected dividends 0.00% 0.00% The risk-free interest rate is based on rates of treasury securities with the same expected term as the options. The Company uses the “simplified method” to calculate the expected term of employee and director stock-based options. The expected term used for consultants is the contractual life. The Company is utilizing an expected volatility figure based on a review of the Company’s historical volatility, over a period of time, equivalent to the expected life of the instrument being valued. The expected dividend yield is based upon the fact that the Company has not historically paid dividends, and does not expect to pay dividends in the near future. Option forfeitures are estimated at the time of valuation and reduce expense ratably over the vesting period. This estimate will be adjusted periodically based on the extent to which actual option forfeitures differ, or are expected to differ, from the previous estimate, when it is material. The Company estimated forfeitures related to options at annual rates ranging from 0% to 5% for options outstanding at December 31, 2016 and 2015. The weighted average estimated grant date fair value of the options granted during the years ended December 31, 2016 and 2015 was $0.77 and $4.18 per share, respectively. During the year ended December 31, 2015, the Company issued an aggregate of 75,919 shares of common stock to several holders of options who elected to exercise options to purchase an aggregate of 75,919 shares of common stock for cash proceeds of $332,000. The options had an exercise price of $4.38 per share. The aggregate intrinsic value of the options exercised was $86,000 for the year ended December 31, 2015. Weighted Weighted Average Average Exercise Remaining Number of Price per Life in Options Option Years Intrinsic Value Outstanding, December 31, 2014 4,818 $ 6.56 Granted 1,905 5.38 Exercised (76) 4.38 Forfeited (416) 5.96 Outstanding, December 31, 2015 6,231 $ 6.26 Granted 1,649 1.05 Exercised - - Forfeited (680) 3.95 Outstanding, December 31, 2016 7,200 $ 5.29 7.1 $ - Exerciseable, December 31, 2016 4,205 $ 6.06 6.3 $ - Options Outstanding Options Exercisable Weighted Weighted Average Outstanding Average Exercisable Range of Exercise Number of Weighted Average Remaining Number of Exercise Price Price Options Exercise Price Life in Years Options $0.80-$0.99 $ 0.87 313 0.86 9.4 131 $1.00-$1.99 1.07 1,159 - - - $2.00-$2.99 2.24 25 2.38 8.9 2 $3.00-$3.99 3.36 501 3.36 6.5 442 $4.00-$4.99 4.60 1,072 4.52 5.3 792 $5.00-$5.99 5.29 625 5.35 6.1 372 $6.00-$6.99 6.60 2,177 6.68 6.8 1,650 $7.00-$7.99 7.75 31 7.75 7.3 21 $8.00-$8.99 8.74 780 8.74 5.7 556 $9.00-$9.99 9.00 253 9.00 6.2 183 $10.00-$26.69 10.96 264 11.01 6.2 56 7,200 6.3 4,205

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	16. Income Taxes The Company files corporate income tax returns in U.S. federal, state and local jurisdictions, including Pennsylvania, and has tax returns subject to examination by tax authorities generally beginning in the year ended December 31, 2013 and through December 31, 2016. However, to the extent the Company utilizes its net operating loss (“NOL”) carryforwards in the future, the tax years in which the attribute was generated may still be adjusted upon examination by the Internal Revenue Service or state tax authorities of the future period tax return in which the attribute is utilized. The income tax (benefit) provision consists of the following (in thousands): For The Years Ended December 31, 2016 2015 Federal: Current $ - $ - Deferred (627 ) (1,509 ) State and local: Current 4 3 Deferred (92 ) (212 ) Income tax provision $ (715 ) $ (1,718 ) For the years ended December 31, 2016 and 2015, the expected tax expense based on the federal statutory rate reconciled with the actual tax expense is as follows: For The Years Ended December 31, 2016 2015 U.S. federal statutory rate 34.0 % 34.0 % State tax rate, net of federal benefit 4.5 % 4.8 % Permanent differences - Change in fair value of warrant liability 0.9 % 2.5 % - Change in fair value of contingent consideration 10.4 % 1.7 % -Acquisition costs 0.0 % (2.1 %) -Intangible impairment (9.3 %) 0.0 % - Other (0.4 %) (0.6 %) Adjustments to deferred taxes (8.2 %) (2.3 %) Change in valuation allowance (29.7 %) (32.1 %) Income tax provision 2.2 % 5.9 % As of December 31, 2016 and 2015, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following (in thousands): As of December 31, 2016 2015 Deferred tax assets: Net operating loss carryforwards $ 40,117 $ 35,284 Stock-based compensation 8,671 7,713 Accruals 541 496 Transaction costs 732 - Other 861 253 Total deferred tax assets 50,922 43,746 Valuation allowance (41,482 ) (32,977 ) Deferred tax assets, net of valuation allowance $ 9,440 $ 10,769 Deferred tax liabilities: Property and equipment (281 ) (409 ) Intangible assets (9,159 ) (10,360 ) Goodwill (749 ) (1,468 ) Total deferred tax liabilities (10,189 ) (12,237 ) Net deferred tax liabilities $ (749 ) $ (1,468 ) For the years ended December 31, 2016 and 2015, the Company had approximately $104.9 million and $93.0 million of federal NOL carryovers, respectively, which substantially begin to expire in 2020 and through 2036. The Company also has state NOL carryovers in multiple jurisdictions, including most materially in Pennsylvania, $24.6 million and $22.9 million, and in Florida, $10.9 million and $9.8 million, as of December 31, 2016 and December 31, 2015, respectively. During 2016 the Company performed an Internal Revenue Code (the “Code”) Section 382 study (“Section 382 study”), and as a result of the study, reduced its NOL carryforwards by $4.8 million, which is the amount of the NOL carryforwards that are expected to expire unutilized pursuant to the Section 382 study. On May 29, 2015, the Company acquired Celleration, Inc. (see Note 5 - Acquisitions In assessing the realization of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will be realized. The ultimate realization of the deferred tax assets is dependent upon the future generation of taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in making this assessment. The deferred tax liabilities related to goodwill and to a tradename cannot be used in this determination since both assets are considered to be assets with an indefinite life for financial reporting purposes. After consideration of all the evidence, both positive and negative, management has recorded a full valuation allowance against net deferred tax assets at December 31, 2016 and December 31, 2015 because management has determined that it is more likely than not that these deferred tax assets will not be realized. The valuation allowance increased by $8.5 million and $8.9 million during the years ended December 31, 2016 and December 31, 2015, respectively, primarily related to increases in NOL carryforwards. The increase during the year ended December 31, 2015 was net of the release of valuation allowances of $1.7 million resulting from the acquisition of Celleration in May 2015 for which we recorded an income tax benefit.

Related Party

Related Party	12 Months Ended
	Dec. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	Related Party In November 2015, the Company entered into a manufacturing supply agreement with a company where a Company director is a member of the Board of Directors. During the years ended December 31, 2016 and 2015, the Company incurred costs of approximately $ 491,000 5,000 102,000 5,000

Concentration of Risk

Concentration of Risk	12 Months Ended
	Dec. 31, 2016
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	18. Concentration of Risk 10

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	19. Fair Value Measurement Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows: Level 1: Observable prices in active markets for identical assets and liabilities. Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities. Impairment Goodwill and other indefinite-lived intangible assets are tested for impairment annually, at the end of the fourth quarter of each fiscal year, and between annual tests if an event occurs or circumstances change that would indicate it is more likely than not that the carrying amount may be impaired. Additionally, t Impairment of the Company’s goodwill and MIST Therapy tradename for the year ended December 31, 2016 was $ 10.9 Warrant liabilities During the year ended December 31, 2015, a warrant to purchase an aggregate of 9,142 31,000 4,000 98.25 0.96 2.52 0.00 During the year ended December 31, 2015, in connection with the Credit Agreement, a five-year warrant to purchase 750,000 5.5138 Debt 2.7 98.25 1.49 5.00 0.00 On December 31, 2015, the Company recomputed the fair value of its warrant liability of outstanding warrants to purchase an aggregate of 816,287 861,000 89.95 1.06 1.54 1.86 4.41 0.00 2.1 On December 31, 2016, the Company recomputed the fair value of its warrant liability of outstanding warrants to purchase an aggregate of 816,287 20,000 65.74 72.16 0.85 1.47 0.86 3.41 0.00 841,000 Acquisitions Warrants that contain exercise reset provisions and contingent consideration liabilities are Level 3 derivative liabilities measured at fair value on a recurring basis using pricing models for which at least one significant assumption is unobservable as defined in ASC 820. The fair value of contingent consideration liabilities that are classified as Level 3 were estimated using a discounted cash flow technique with significant inputs that are not observable in the market and thus represents a Level 3 fair value measurement as defined in ASC 820. The significant inputs in the Level 3 measurement not supported by market activity include the probability assessments of expeced future cash flows related to the acquisitions, appropriately discounted considering the uncertainties associated with the obligation, and as calculated in accordance with the terms of the acquisition agreements. The development and determination of the unobservable inputs for Level 3 fair value measurements and the fair value calculations are the responsibility of the Company’s Chief Financial Officer and are approved by the Chief Executive Officer. The following table sets forth a summary of the changes in the fair value of Level 3 warrant liabilities that are measured at fair value on a recurring basis (in thousands): December 31, 2016 2015 Warrant Liabilities Beginning balance as of January 1, $ 861 $ 304 Change in fair value of warrant liability (841) (2,095) Value of warrants issued - 2,683 Value of warrants exercised - (31) Ending balance as of December 31, $ 20 $ 861 December 31, 2016 2015 Contingent Consideration Beginning balance as of January 1, $ 17,028 $ 2,932 Initial fair value of contingent consideration - 15,570 Payments of contingent consideration (5,147) - Change in fair value of contingent consideration (10,065) (1,474) Ending balance as of December 31, $ 1,816 $ 17,028 Assets and liabilities measured at fair value on a recurring basis are as follows (in thousands): December 31, 2016 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 20 Contingent consideration - - 1,816 Total liabilities $ - $ - $ 1,836 December 31, 2015 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 861 Contingent consideration - - 17,028 Total liabilities $ - $ - $ 17,889 Assets measured at fair value on a non-recurring basis are as follows (in thousands): December 31, 2016 Level 1 Level 2 Level 3 Total Impairments Assets: Intangible assets $ - $ - $ 28,498 $ 1,688 Goodwill - - 11,959 9,207 Total assets $ - $ - $ 40,457 $ 10,895 December 31, 2015 Level 1 Level 2 Level 3 Assets: Intangible assets $ - $ - $ 33,667 Goodwill - - 21,166 Total assets $ - $ - $ 54,833

Defined Contribution Plan

Defined Contribution Plan	12 Months Ended
	Dec. 31, 2016
Compensation and Retirement Disclosure [Abstract]
Pension and Other Postretirement Benefits Disclosure [Text Block]	20. Defined Contribution Plan The Company maintains the Alliqua, Inc. 401(k) Profit Sharing Plan and Trust (“Plan”) in accordance with the provisions of Section 401(k) of the Code. The Plan covers substantially all full-time employees of the Company. Participants may contribute up to 100% of their total compensation to the Plan, not to exceed the limit as defined in the Code. 50 6 105,000 75,000

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2016
Subsequent Events [Abstract]
Subsequent Events [Text Block]	21. Subsequent Events Senior Secured Term Loan Facility On January 26, 2017, as amended on March 7, 2017, the Company entered into an agreement with Perceptive whereby Perceptive agreed to forbear from exercising its rights and remedies related to the default of the Credit Agreement until April 30, 2017 or the date when the lender becomes aware of any other default. The lender reserved the rights, commencing with the occurrence of any of these events, to pursue any rights and remedies available to it, including, but not limited to, declaring all or any portion of the outstanding principal amount to be immediately due and payable, imposing a default rate of interest as specified in the credit agreement, or pursing the lender’s rights and remedies as a secured party under the UCC as a secured lender. In connection with this agreement, the Warrant issued at the entry of the Credit Agreement was amended to allow Perceptive to purchase two 0.001 0.50 The amended and restated warrant contains a weighted average anti-dilution feature whereby the exercise price of the amended and restated warrant is subject to reduction if we issue shares of common stock (or securities convertible into common stock) in the future at a price below the current exercise price of such warrant. Notes Receivable In January 2017, the Company provided Soluble with an additional $ 350,000 6 1.4 Private Placement On February 27, 2017, the Company closed a private placement of 5,540,000 0.50 2,770,000

Summary of Significant Accoun30

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Use of Estimates, Policy [Policy Text Block]	Use of Estimates in the Financial Statements The preparation of the consolidated financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. These estimates and assumptions include valuing equity securities and derivative financial instruments issued in financing transactions, allowance for doubtful accounts, inventory reserves, deferred taxes and related valuation allowances, and the fair values of long lived assets, intangibles, goodwill and contingent consideration. Actual results could differ from the estimates.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash and Cash Equivalents The Company considers all highly liquid investments with maturities of three months or less when purchased to be cash equivalents. The Company’s balance of cash and cash equivalents at December 31, 2016 and 2015 consisted principally of bank deposits. From time to time, the Company’s cash account balances may be uninsured or in deposit accounts that exceed Federal Deposit Insurance Corporation guarantee limit. The Company reduces its exposure to credit risk by maintaining its cash deposits with major financial institutions and monitoring their credit ratings.
Receivables, Policy [Policy Text Block]	Trade Accounts Receivable Trade accounts receivable are stated at the amount the Company expects to collect and 213,000 175,000
Inventory, Policy [Policy Text Block]	Inventory Inventory is stated at the lower of cost, the value determined by the first-in, first-out method, or market. At each balance sheet date, the Company evaluates inventories for excess quantities, obsolescence or shelf life expiration. This evaluation includes analysis of historical sales levels by product, projections of future demand, the risk of technological or competitive obsolescence for products, general market conditions, and a review of the shelf life expiration dates for products. To the extent that management determines there are excess or obsolete inventory or quantities with a shelf life that is too near its expiration for the Company to reasonably expect that it can sell those products prior to their expiration, the Company adjusts the carrying value to estimated net realizable value.
Property, Plant and Equipment, Policy [Policy Text Block]	Improvements and Equipment Improvements and equipment are recorded at cost. Depreciation of equipment is computed utilizing the straight-line method over the estimated useful lives of the assets. Amortization of leasehold improvements is computed utilizing the straight-line method over the lesser of the lease term or the estimated useful life. Repairs and maintenance costs are expensed as incurred. The cost of major additions and improvements is capitalized, while maintenance and repair costs that do not improve or extend the lives of the respective assets are charged to operations as incurred.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	The Company records goodwill and other indefinite-lived assets in connection with business combinations. Goodwill, which represents the excess of acquisition cost over the fair value of the net tangible and intangible assets of acquired companies, is not amortized. Indefinite-lived assets are stated at fair value as of the date acquired in a business combination. The Company assesses the recoverability of goodwill and certain indefinite-lived intangible assets annually in the fourth quarter and between annual tests if an event occurs or circumstances change that would indicate the carrying amount may be impaired. Impairment testing for goodwill is done at a reporting unit level. Under Financial Accounting Standards Board (“FASB”) guidance for goodwill and intangible assets, a reporting unit is defined as an operating segment or one level below the operating segment, called a component. However, two or more components of an operating segment will be aggregated and deemed a single reporting unit if the components have similar economic characteristics. The Company operates as one reporting unit. Authoritative accounting guidance allows the Company to first assess qualitative factors to determine whether it is necessary to perform the more detailed two-step quantitative goodwill impairment test. The Company performs the quantitative test if its qualitative assessment determined it is more likely than not that a reporting unit’s fair value is less than its carrying amount. The Company may elect to bypass the qualitative assessment and proceed directly to the quantitative test for any reporting unit or asset. The quantitative goodwill impairment test, if necessary, is a two-step process. The first step is to identify the existence of a potential impairment by comparing the fair value of a reporting unit (the estimated fair value of a reporting unit is calculated using a discounted cash flow model) with its carrying amount, including goodwill. If the fair value of a reporting unit exceeds its carrying amount, the reporting unit’s goodwill is considered not to be impaired and performance of the second step of the quantitative goodwill impairment test is unnecessary. However, if the carrying amount of a reporting unit exceeds its fair value, the second step of the quantitative goodwill impairment test is performed to measure the amount of impairment loss to be recorded, if any. The second step of the quantitative goodwill impairment test compares the implied fair value of the reporting unit’s goodwill with the carrying amount of that goodwill. If the carrying amount of the reporting unit’s goodwill exceeds its implied fair value, an impairment loss is recognized in an amount equal to that excess. The implied fair value of goodwill is determined using the same approach as employed when determining the amount of goodwill that would be recognized in a business combination. That is, the fair value of the reporting unit is allocated to all of its assets and liabilities as if the reporting unit had been acquired in a business combination and the fair value was the purchase price paid to acquire the reporting unit. For the 2016 annual goodwill and certain indefinite-lived intangible assets impairment tests, the Company elected to bypass the qualitative assessment and proceeded directly to the quantitative analysis using a discounted cash flow method to estimate fair value. As a result of this test, the Company’s goodwill was determined to be impaired and an impairment charge of $ 9.2 1.7 10.9 At December 31, 2016 the remaining recorded goodwill was $ 12.0 21.2 Goodwill Balance as of December 31, 2014 $ 4,100 Goodwill acquired (1) 17,066 Balance as of December 31, 2015 $ 21,166 Impairment loss (9,207) Balance as of December 31, 2016 $ 11,959 (1) Goodwill acquired as a result of the acquisition of Celleration in May 2015. See Note 5 – Acquisitions .
Impairment or Disposal of Long-Lived Assets, Including Intangible Assets, Policy [Policy Text Block]	Long-Lived Assets Long-lived assets, such as property and equipment, and intangibles subject to amortization, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company’s long-lived intangible assets primarily consist of developed technology, customer lists/relationships, non-compete agreements, trade names and trademarks and are amortized ratably over a range of one to ten years which approximates customer attrition rate and technology obsolescence. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset to estimated undiscounted future cash flows expected to be generated by the asset. If the carrying amount of an asset exceeds its estimated future cash flows, an impairment charge is recognized of the amount by which the carrying amount of the asset exceeds the fair value of the asset. The Company continually evaluates whether events or changes in circumstances might indicate that the remaining estimated useful life of long-lived assets may warrant revision, or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, the Company uses an estimate of the related undiscounted cash flows in measuring whether the long-lived asset should be written down to fair value. Measurement of the amount of impairment is based on generally accepted valuation methodologies, as deemed appropriate. The factors used to determine fair value are subject to management’s judgement and expertise and include, but are not limited to, the present value of future cash flows, net of estimated operating costs, anticipated capital expenditures and various discount rates commensurate with the risk and current market conditions associated with realizing the expected cash flows projected. There were no long-lived asset impairment charges recorded during the years ended December 31, 2016 or 2015, other than the impairment of the MIST Therapy tradename during the year ended December 31, 2016 described above and in Note 10- Intangible Assets.
Fair Value of Financial Instruments, Policy [Policy Text Block]	The carrying amounts reported in the consolidated balance sheets for cash and cash equivalents, accounts receivable and accounts payable and accrued expenses approximate fair value based on the short-term maturity of these instruments. Fair value is defined as the price that would be received upon selling an asset or the price paid to transfer a liability on the measurement date. It focuses on the exit price in the principal or most advantageous market for the asset or liability in an orderly transaction between willing market participants. A three-tier fair value hierarchy is established as a basis for considering such assumptions and for inputs used in the valuation methodologies in measuring fair value. This hierarchy requires entities to maximize the use of observable inputs and minimize the use of unobservable inputs. The three levels of inputs used to measure fair values are as follows: Level 1: Observable prices in active markets for identical assets and liabilities. Level 2: Observable inputs other than quoted prices in active markets for identical assets and liabilities. Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets and liabilities.
Revenue Recognition, Policy [Policy Text Block]	Revenue is recognized when persuasive evidence of an arrangement exists, delivery has occurred, title and risk of loss have passed to the customer, there is a fixed or determinable sales price, and collectability of that sales price is reasonably assured. The Company also recognizes revenue under a variety of rental programs of the MIST Therapy system, which is recognized over the term of the rental agreement.
Selling, General and Administrative Expenses, Policy [Policy Text Block]	Costs associated with the production and procurement of product are included in cost of goods sold, including shipping and handling costs such as inbound freight costs, purchasing and receiving costs, inspection costs and other product procurement related charges. All other expenses are included in selling, general and administrative expenses, as the predominant expenses associated therewith are general and administrative in nature.
Advertising Cost, Policy, Expensed Advertising Cost [Policy Text Block]	Advertising Advertising costs are expensed as incurred and are included in selling, general and administrative expenses. Advertising expenses for the years ended December 31, 2016 and 2015 were approximately $ 2.4 2.1
Shipping and Handling Cost, Policy [Policy Text Block]	Shipping and Handling Amounts billed to customers for shipping and handling are included in revenues. The related shipping and freight charges incurred by the Company are included in cost of goods sold and were not material for either the years ended December 31, 2016 or 2015.
Research and Development Expense, Policy [Policy Text Block]	Research and Development All research and product development costs are expensed as incurred. For the year ended December 31, 2016 and 2015, the Company incurred research and development costs of approximately $ 859,000 715,000
Income Tax, Policy [Policy Text Block]	Income Taxes The Company accounts for income taxes pursuant to the asset and liability method which requires us to recognize current tax liabilities or receivables for the amount of taxes we estimate are payable or refundable for the current year and deferred tax assets and liabilities for the expected future tax consequences attributable to temporary differences between the financial statement carrying amounts and their respective tax bases of assets and liabilities and the expected benefits of net operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in operations in the period enacted. A valuation allowance is provided when it is more likely than not that a portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income and the reversal of deferred tax liabilities during the period in which related temporary differences become deductible. The Company adopted the provisions of Accounting Standards Codification Topic 740 (“ASC 740”) related to the accounting for uncertainty in income taxes recognized in an enterprise’s consolidated financial statements. ASC 740 prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns. The benefit of tax positions taken or expected to be taken in the Company’s income tax returns are recognized in the financial statements if such positions are more likely than not of being sustained upon examination by taxing authorities. Differences between tax positions taken or expected to be taken in a tax return and the benefit recognized and measured pursuant to the interpretation are referred to as “unrecognized benefits”. A liability is recognized (or amount of net operating loss carryover or amount of tax refundable is reduced) for an unrecognized tax benefit because it represents an enterprise’s potential future obligation to the taxing authority for a tax position that was not recognized as a result of applying the provisions of ASC 740. Interest costs and related penalties related to unrecognized tax benefits are required to be calculated, if applicable. The Company’s policy is to classify assessments, if any, for tax related interest as interest expense and penalties as selling, general and administrative expenses. No interest or penalties were recorded during the years ended December 31, 2016 and 2015. As of December 31, 2016 and December 31, 2015, no liability for unrecognized tax benefits was required to be reported. The Company does not expect any significant changes in its unrecognized tax benefits in the next year.
Common Stock Purchase Warrant [Policy Text Block]	Common Stock Purchase Warrants The Company assesses classification of common stock purchase warrants at each reporting date to determine whether a change in classification between assets and liabilities or equity is required. The Company’s free standing derivatives consist of warrants to purchase common stock that were issued pursuant to a Securities Purchase Agreement on November 8, 2012 and pursuant to a Credit Agreement on May 29, 2015. The Company evaluated the common stock purchase warrants to assess their proper classification in the consolidated balance sheet and determined that the common stock purchase warrants contain exercise reset provisions. Accordingly, these instruments have been classified as warrant liabilities in the accompanying consolidated balance sheets as of December 31, 2016 and 2015. The Company re-measures warrant liabilities at each reporting and exercise date, with changes in fair value recognized in earnings for each reporting period.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Stock-Based Compensation The Company measures the cost of services received in exchange for an award of equity instruments based on the fair value of the award. For employees and directors, the fair value of the award is measured on the grant date and for non-employees, the fair value of the award is generally re-measured on interim financial reporting dates and vesting dates until the service period is complete. The fair value amount is then recognized over the period services are required to be provided in exchange for the award, usually the vesting period. The Company recognizes stock-based compensation expense on a graded-vesting basis over the requisite service period for each separately vesting tranche of each award. Stock-based compensation expense is reflected within cost of revenues and operating expenses in the consolidated statements of operations. The Company recognizes stock-based compensation expense for awards with performance conditions if and when the Company concludes that it is probable that the performance condition will be achieved. The Company reassesses the probability of vesting at each reporting period for awards with performance conditions and adjusts stock-based compensation expense based on its probability assessment.
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Principles In January 2017, the FASB issued Accounting Standards Update (ASU) 2017-04: “Intangibles – Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment” (“ASU 2017-04”), which removes Step 2 from the goodwill impairment test. It is effective for annual and interim periods beginning after December 15, 2019. Early adoption is permitted for interim or annual goodwill impairment test performed with a measurement date after January 1, 2017. The Company does not expect this new guidance to have a material impact on its financial positions or results of operations. In January 2017, the FASB issued ASU 2017-01 “Business Combinations (Topic 805): Clarifying the Definition of a Business”, which clarifies the definition of a business to assist entities with evaluating whether transactions should be accounted for as acquisitions or disposals of assets or businesses. The standard introduces a screen for determining when assets acquired are not a business and clarifies that a business must include, at a minimum, an input and a substantive process that contribute to an output to be considered a business. This standard is effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. The Company does not expect this new guidance to have a material impact on its financial position, results of operations or financial statement disclosures. In December 2016, the FASB issued ASU 2016-18 “Statement of Cash Flows (Topic 230): Restricted Cash (a consensus of the FASB Emerging Issues Task Force,” which clarifies the presentation requirements of restricted cash within the statement of cash flows. The changes in restricted cash and restricted cash equivalents during the period should be included in the beginning and ending cash and cash equivalents balance reconciliation on the statement of cash flows. When cash, cash equivalents, restricted cash or restricted cash equivalents are presented in more than one line item within the statement of financial position, an entity shall calculate a total cash amount in a narrative or tabular format that agrees to the amount shown on the statement of cash flows. Details on the nature and amounts of restricted cash should also be disclosed. This standard is effective for fiscal years beginning after December 15, 2017, including interim periods within that reporting period. The Company does not expect this new guidance to have a material impact on its financial position or results of operations. In August 2016, the FASB issued ASU No. 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments.” ASU No. 2016-15 clarifies and provides specific guidance on eight cash flow classification issues that are not currently addressed by current GAAP and thereby reduce the current diversity in practice. ASU No. 2016-15 is effective for public business entities for annual periods, including interim periods within those annual periods, beginning after December 15, 2017, with early application permitted. This guidance is applicable to the Company’s fiscal year beginning January 1, 2018. The Company does not anticipate that this guidance will have a material impact on its consolidated financial statements. In March 2016, the FASB issued ASU No. 2016-09, “Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting” (“ASU 2016-09”). The standard is intended to simplify several areas of accounting for share-based compensation arrangements, including the income tax impact, classification on the statement of cash flows and forfeitures. ASU 2016-09 is effective for fiscal years, and interim periods within those years, beginning after December 15, 2016, which for the Company will commence with the year beginning January 1, 2018, with early adoption permitted commencing January 1, 2017. The Company is currently evaluating the standard to determine the impact of its adoption on the consolidated financial statements. In February 2016, the FASB issued Accounting Standards Update 2016-02, “Leases (Topic 842)” (“ASU 2016-02”). The standard requires a lessee to recognize assets and liabilities on the balance sheet for leases with lease terms greater than 12 months. The standard is effective for annual reporting periods beginning after December 15, 2018, which for the Company will commence with the year beginning January 1, 2019, with early application permitted. The adoption will require a modified retrospective approach for leases that exist or are entered into after the beginning of the earliest period presented. The Company is currently evaluating the standard to determine the impact of the adoption on the consolidated financial statements. In November 2015, the FASB issued Accounting Standards Update 2015-17, “Income Taxes (Topic 740): Balance Sheet Classification of Deferred Taxes” (“ASU 2015-07”), an update to accounting guidance to simplify the presentation of deferred income taxes. The guidance requires an entity to classify all deferred tax liabilities and assets, along with any valuation allowance, as noncurrent in the balance sheet. The guidance is effective for public companies with annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. Early application is permitted. The Company has elected to early adopt ASU 2015-17 during the year ended December 31, 2015 with retrospective application. The adoption of ASU 2015-17 did not have a material impact on the Company’s consolidated financial statements. In August 2014, the FASB issued ASU 2014-15, “Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern”. ASU 2014-15 is intended to define management’s responsibility to evaluate whether there is substantial doubt about an organization’s ability to continue as a going concern and to provide related footnote disclosures. For all entities, the ASU is effective for annual periods ending after December 15, 2016 and interim periods within annual periods beginning after December 15, 2016. Early adoption is permitted. The Company adopted this standard for the year ended December 31, 2016. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606)” (“ASU 2014-09”). ASU 2014-09 supersedes the revenue recognition requirements in ASC Topic 605, “Revenue Recognition” and some cost guidance included in ASC Subtopic 605-35, “Revenue Recognition - Construction-Type and Production-Type Contracts.” The core principle of ASU 2014-09 is that revenue is recognized when the transfer of goods or services to customers occurs in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. ASU 2014-09 requires the disclosure of sufficient information to enable readers of the Company’s financial statements to understand the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. ASU 2014-09 also requires disclosure of information regarding significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. ASU 2014-09 provides two methods of retrospective application. The first method would require the Company to apply ASU 2014-09 to each prior reporting period presented. The second method would require the Company to retrospectively apply ASU 2014-09 with the cumulative effect recognized at the date of initial application. ASU 2014-09 will be effective for the Company beginning in fiscal 2019 as a result of ASU 2015-14, “Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date,” which was issued by the FASB in August 2015 and extended the original effective date by one year. The Company is currently evaluating the impact of adopting the available methodologies of ASU 2014-09 and 2015-14 upon its financial statements in future reporting periods. The Company has not yet selected a transition method. The Company is in the process of evaluating the new standard against its existing accounting policies, including the timing of revenue recognition, and its contracts with customers to determine the effect the guidance will have on its financial statements and what changes to systems and controls may be warranted. There have been four new ASUs issued amending certain aspects of ASU 2014-09, ASU 2016-08, “Principal versus Agent Considerations (Reporting Revenue Gross Versus Net),” was issued in March, 2016 to clarify certain aspects of the principal versus agent guidance in ASU 2014-09. In addition, ASU 2016-10, “Identifying Performance Obligations and Licensing,” issued in April 2016, amends other sections of ASU 2014-09 including clarifying guidance related to identifying performance obligations and licensing implementation. ASU 2016-12, “Revenue from Contracts with Customers - Narrow Scope Improvements and Practical Expedients” provides amendments and practical expedients to the guidance in ASU 2014-09 in the areas of assessing collectability, presentation of sales taxes received from customers, noncash consideration, contract modification and clarification of using the full retrospective approach to adopt ASU 2014-09. Finally, ASU 2016-20, “Technical Corrections and Improvements to Topic 606, Revenue from Contracts with Customers,” was issued in December 2016, and provides elections regarding the disclosures required for remaining performance obligations in certain cases and also makes other technical corrections and improvements to the standard. With its evaluation of the impact of ASU 2014-09, the Company will also consider the impact on its financial statements related to the updated guidance provided by these four new ASUs.

Summary of Significant Accoun31

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2016
Accounting Policies [Abstract]
Schedule of Goodwill [Table Text Block]	The changes in the carrying amount of goodwill for the years ended December 31, 2016 and 2015, are as follows (in thousands): Goodwill Balance as of December 31, 2014 $ 4,100 Goodwill acquired (1) 17,066 Balance as of December 31, 2015 $ 21,166 Impairment loss (9,207) Balance as of December 31, 2016 $ 11,959 (1) Goodwill acquired as a result of the acquisition of Celleration in May 2015. See Note 5 – Acquisitions .

Net Loss Per Common Share (Tabl

Net Loss Per Common Share (Tables)	12 Months Ended
	Dec. 31, 2016
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	The following securities are excluded from the calculation of weighted average dilutive common shares because their inclusion would have been anti-dilutive: As of December 31, 2016 2015 Stock options 7,199,286 6,230,549 Warrants 3,365,407 3,372,550 Non-vested restricted stock 1,470,228 691,725 Total 12,034,921 10,294,824

Acquisitions (Tables)

Acquisitions (Tables)	12 Months Ended
	Dec. 31, 2016
Business Acquisition, Pro Forma Information [Table Text Block]	The unaudited pro forma results of operations from continuing operations for the year ended December 31, 2015 are as follows (in thousands, except per share amounts): Year Ended December 31, 2015 Revenues $ 16,266 Net loss $ (31,877) Net loss per share $ (1.31)
Acquisition of Celleration, Inc [Member]
Schedule of Business Acquisitions, by Acquisition [Table Text Block]	The following summarizes the final allocation of the purchase price based on fair value of the assets acquired and liabilities assumed (in thousands): Consideration: Common stock $ 15,208 Cash paid 15,476 Fair value of contingent consideration 15,570 Total consideration 46,254 Cash 528 Trade receivables 877 Inventory 341 Other current assets 207 Improvements and equipment 411 Tradenames 3,601 Technology 27,143 Customer relationships 1,208 Goodwill 17,066 Accounts payable (308) Accrued expenses and other liabilities (1,698) Deferred tax liability (3,122) Net assets acquired $ 46,254

Discontinued Operations (Tables

Discontinued Operations (Tables)	12 Months Ended
	Dec. 31, 2016
Discontinued Operations and Disposal Groups [Abstract]
Schedule of Gain Loss on Disposal of Discontinued Operations [Table Text Block]	During the year ended December 31, 2016, the Company recorded a gain of approximately $ 3.3 0 Proceeds from sale Consideration for inventory $ 603 Consideration for intangible assets 3,500 Total Consideration 4,103 Less: Net book value of assets sold to BSN Inventory, net (603) Intangibles, net (189) Total net book value of assets (792) Gain on sale of assets $ 3,311
Disposal Groups, Including Discontinued Operations [Table Text Block]	Summarized operating results of discontinued operations for the years ended December 31, 2016 and 2015 are presented in the following table (in thousands): Years Ended December 31, 2016 2015 Revenue, net of returns, allowances and discounts $ 1,709 $ 2,864 Cost of revenues 536 823 Gross profit 1,173 2,041 Selling, general and administrative 323 841 Income from discontinued operations, net of tax $ 850 $ 1,200 Summarized assets and liabilities of discontinued operations as of December 31, 2015 are presented in the table below, (in thousands): December 31, 2015 Accounts receivable, net $ 457 Inventory, net 858 Total current assets 1,315 Intangible assets, net 227 Total assets 1,542 Accounts payable 44 Accrued expenses and other current liabilities 59 Total current liabilities $ 103

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consists of the following (dollars in thousands): December 31, December 31, 2016 2015 Raw materials $ 135 $ 241 Work in process 173 228 Finished goods 2,394 1,865 Less: Inventory reserve for excess and slow moving inventory - (59) Total $ 2,702 $ 2,275

Improvements and Equipment, n36

Improvements and Equipment, net (Tables)	12 Months Ended
	Dec. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	Improvements and equipment consist of the following (in thousands): December 31, Useful Life 2016 2015 (Years) Machinery and equipment 3-10 $ 5,041 $ 3,621 Office furniture and equipment 3-10 337 88 Leasehold improvements (A) 595 253 5,973 3,962 Less: Accumulated depreciation and amortization (3,881) (2,115) Improvements and equipment, net $ 2,092 $ 1,847 (A) Leasehold improvements are amortized over the shorter of the remaining lease term or estimated useful life.

Intangible Assets (Tables)

Intangible Assets (Tables)	12 Months Ended
	Dec. 31, 2016
Finite-Lived Intangible Assets, Net [Abstract]
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]	The gross carrying amount and accumulated amortization of intangible assets are as follows (in thousands): December 31, 2016 Useful Life Gross Accumulated Net Carrying (Years) Amount Amortization Impairment Amount Technology 10 $ 32,539 $ (7,312) $ - $ 25,227 Customer relationships 9-12 1,984 (639) - 1,345 Tradename 3 111 (98) - 13 Tradename related to MIST Therapy (1) 3 3,601 - (1,688) 1,913 Non-compete 1 208 (208) - - Total intangible assets 38,443 (8,257) (1,688) 28,498 December 31, 2015 Useful Life Gross Accumulated Net Carrying (Years) Amount Amortization Impairment Amount Intangible assets subject to amortization: Technology 10 $ 32,539 $ (4,057) $ - $ 28,482 Customer relationships 9-12 1,984 (449) - 1,535 Tradename 3 111 (62) - 49 Non-compete 1 208 (208) - - $ 34,842 $ (4,776) $ - $ 30,066 Indefinite-lived intangible assets: Tradename related to MIST Therapy (1) Indefinite 3,601 - - 3,601 Total indefinite-lived intangible assets 3,601 - - 3,601 Total intangible assets $ 38,443 $ (4,776) $ - $ 33,667 (1) In December 2016, the Company determined the tradename related to MIST Therapy was no longer an indefinite-lived intangible asset. The Company assigned a remaining useful of approximately 1.5
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]	Amortization expense in each of the five years and thereafter subsequent to December 31, 2016 related to the Company’s intangible assets is expected to be as follows (in thousands): Expected Amortization Expense 2017 $ 4,807 2018 4,007 2019 3,169 2020 3,144 2021 3,098 Thereafter 10,273 Total $ 28,498

Accrued Expenses (Tables)

Accrued Expenses (Tables)	12 Months Ended
	Dec. 31, 2016
Accrued Liabilities, Current [Abstract]
Schedule of Accrued Liabilities [Table Text Block]	Accrued expenses and other current liabilities consist of the following (in thousands): December 31, December 31, 2016 2015 Salaries, benefits and incentive compensation $ 3,070 $ 2,118 Milestone payment to licensor 1,000 - Professional fees 692 671 Royalty fees 197 52 Deferred revenue 181 92 Other 146 138 Total accrued expenses and other current liabilities $ 5,286 $ 3,071

Operating Leases (Tables)

Operating Leases (Tables)	12 Months Ended
	Dec. 31, 2016
Leases, Operating [Abstract]
Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]	Future minimum lease payments, excluding expense reimbursements, under noncancelable operating leases at December 31, 2016 are as follows (in thousands): 2017 $ 500 2018 506 2019 512 2020 519 2021 525 Thereafter 1,311 Total $ 3,873

Debt (Tables)

Debt (Tables)	12 Months Ended
	Dec. 31, 2016
Debt Instruments [Abstract]
Schedule of Debt [Table Text Block]	Debt consists of the following (in thousands): December 31, December 31, 2016 2015 Long-term debt $ 13,752 $ 15,500 Unamortized debt issuance and discount costs (2,211) (3,374) Total $ 11,541 $ 12,126

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2016
Nonvested Restricted Stock Shares Activity [Table Text Block]	The following table summarizes the restricted stock issued as compensation during the years ended December 31, 2016 and 2015 (in thousands): Issuance Grantee Shares Vesting Grant Date Date Type Issued Term Value 02/06/15 Employee 600 [1] $ 3,738 06/15/15 Employee 120 [2] 630 2015 - Restricted Stock - Total 720 $ 4,368 02/09/16 Employee 325 [3] $ 474 05/11/16 Employee 700 [4] 602 2016 - Restricted Stock - Total 1,025 $ 1,076 [1] Vests in three equal annual installments, with one-third vesting on each of February 6, 2016, February 6, 2017 and February 6, 2018. [2] Vests in equal quarterly installments, with one-fourth vesting immediately and the remaining vesting equally over the next 3 years on the anniversaries of the date of grant. [3] Vests on the earlier of (a) the first anniversary of the date of grant or (b) the participant’s termination of service by the Company without cause. [4] Vests pursuant to the satisfaction of certain performance conditions.
Schedule of Nonvested Share Activity [Table Text Block]	A summary of restricted stock award activity during the years ended December 31, 2016 and 2015 is presented below (in thousands, except per share data): Weighted Average Grant Date Total Grant Number of Fair Value Per Date Fair Shares Share Value Non-vested, December 31, 2014 188 $ 7.03 $ 1,322 Granted 720 6.07 4,368 Vested (216) 6.76 (1,464) Forfeited - - - Non-vested, December 31, 2015 692 $ 6.11 $ 4,226 Granted 1,025 1.05 1,076 Vested (238) 6.00 (1,428) Forfeited (8) 1.46 (12) Non-vested, December 31, 2016 1,471 $ 2.43 $ 3,862
Warrant [Member]
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table presents information related to warrants at December 31, 2016 (in thousands, except years and per warrant data): Warrants Outstanding Warrants Exercisable Weighted Average Outstanding Remaining Exercisable Number of Life in Number of Exercise Price Warrants Years Warrants $2.19-$2.99 93 0.8 93 $3.00-$3.99 77 0.1 77 $4.00-$4.99 977 1.5 977 $5.00-$5.99 1,791 2.5 1,791 $6.00-$10.50 428 2.3 428 3,366 2.1 3,366
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	In applying the Black-Scholes option pricing model to stock options granted, the Company used the following assumptions: Year Ended December 31, 2016 2015 Risk free interest rate 1.14%-2.06% 1.19% - 2.11% Expected term (years) 5.04-6.50 5.00-6.50 Expected volatility 89.53% - 89.95% 93.70% - 98.25% Expected dividends 0.00% 0.00%
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the warrant activity during the years ended December 31, 2016 and 2015 is presented below (in thousands, except years and per warrant data): Weighted Weighted Average Average Remaining Number of Exercise Life in Intrinsic Warrants Price per Warrant Years Value Outstanding, December 31, 2014 2,675 $ 5.76 Issued 750 5.51 Exercised (16) 2.19 Cancelled (36) 7.88 Outstanding, December 31, 2015 3,373 $ 5.70 Issued - - Exercised - - Cancelled (7) 8.75 Outstanding, December 31, 2016 3,366 $ 5.69 2.1 $ - Exercisable, December 31, 2016 3,366 $ 5.69 2.1 $ -
Employee Stock Option [Member]
Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]	The following table presents information related to stock options at December 31, 2016 below (in thousands, except years and per option data): Options Outstanding Options Exercisable Weighted Weighted Average Outstanding Average Exercisable Range of Exercise Number of Weighted Average Remaining Number of Exercise Price Price Options Exercise Price Life in Years Options $0.80-$0.99 $ 0.87 313 0.86 9.4 131 $1.00-$1.99 1.07 1,159 - - - $2.00-$2.99 2.24 25 2.38 8.9 2 $3.00-$3.99 3.36 501 3.36 6.5 442 $4.00-$4.99 4.60 1,072 4.52 5.3 792 $5.00-$5.99 5.29 625 5.35 6.1 372 $6.00-$6.99 6.60 2,177 6.68 6.8 1,650 $7.00-$7.99 7.75 31 7.75 7.3 21 $8.00-$8.99 8.74 780 8.74 5.7 556 $9.00-$9.99 9.00 253 9.00 6.2 183 $10.00-$26.69 10.96 264 11.01 6.2 56 7,200 6.3 4,205
Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]	A summary of the stock option activity during the years ended December 31, 2016 and 2015 is presented below (in thousands, except years and per option data): Weighted Weighted Average Average Exercise Remaining Number of Price per Life in Options Option Years Intrinsic Value Outstanding, December 31, 2014 4,818 $ 6.56 Granted 1,905 5.38 Exercised (76) 4.38 Forfeited (416) 5.96 Outstanding, December 31, 2015 6,231 $ 6.26 Granted 1,649 1.05 Exercised - - Forfeited (680) 3.95 Outstanding, December 31, 2016 7,200 $ 5.29 7.1 $ - Exerciseable, December 31, 2016 4,205 $ 6.06 6.3 $ -

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2016
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	The income tax (benefit) provision consists of the following (in thousands): For The Years Ended December 31, 2016 2015 Federal: Current $ - $ - Deferred (627 ) (1,509 ) State and local: Current 4 3 Deferred (92 ) (212 ) Income tax provision $ (715 ) $ (1,718 )
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	For the years ended December 31, 2016 and 2015, the expected tax expense based on the federal statutory rate reconciled with the actual tax expense is as follows: For The Years Ended December 31, 2016 2015 U.S. federal statutory rate 34.0 % 34.0 % State tax rate, net of federal benefit 4.5 % 4.8 % Permanent differences - Change in fair value of warrant liability 0.9 % 2.5 % - Change in fair value of contingent consideration 10.4 % 1.7 % -Acquisition costs 0.0 % (2.1 %) -Intangible impairment (9.3 %) 0.0 % - Other (0.4 %) (0.6 %) Adjustments to deferred taxes (8.2 %) (2.3 %) Change in valuation allowance (29.7 %) (32.1 %) Income tax provision 2.2 % 5.9 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	As of December 31, 2016 and 2015, the Company’s deferred tax assets consisted of the effects of temporary differences attributable to the following (in thousands): As of December 31, 2016 2015 Deferred tax assets: Net operating loss carryforwards $ 40,117 $ 35,284 Stock-based compensation 8,671 7,713 Accruals 541 496 Transaction costs 732 - Other 861 253 Total deferred tax assets 50,922 43,746 Valuation allowance (41,482 ) (32,977 ) Deferred tax assets, net of valuation allowance $ 9,440 $ 10,769 Deferred tax liabilities: Property and equipment (281 ) (409 ) Intangible assets (9,159 ) (10,360 ) Goodwill (749 ) (1,468 ) Total deferred tax liabilities (10,189 ) (12,237 ) Net deferred tax liabilities $ (749 ) $ (1,468 )

Fair Value Measurement (Tables)

Fair Value Measurement (Tables)	12 Months Ended
	Dec. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]	December 31, 2016 2015 Warrant Liabilities Beginning balance as of January 1, $ 861 $ 304 Change in fair value of warrant liability (841) (2,095) Value of warrants issued - 2,683 Value of warrants exercised - (31) Ending balance as of December 31, $ 20 $ 861 December 31, 2016 2015 Contingent Consideration Beginning balance as of January 1, $ 17,028 $ 2,932 Initial fair value of contingent consideration - 15,570 Payments of contingent consideration (5,147) - Change in fair value of contingent consideration (10,065) (1,474) Ending balance as of December 31, $ 1,816 $ 17,028
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]	Assets and liabilities measured at fair value on a recurring basis are as follows (in thousands): December 31, 2016 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 20 Contingent consideration - - 1,816 Total liabilities $ - $ - $ 1,836 December 31, 2015 Level 1 Level 2 Level 3 Liabilities: Warrant liabilities $ - $ - $ 861 Contingent consideration - - 17,028 Total liabilities $ - $ - $ 17,889 December 31, 2016 Level 1 Level 2 Level 3 Total Impairments Assets: Intangible assets $ - $ - $ 28,498 $ 1,688 Goodwill - - 11,959 9,207 Total assets $ - $ - $ 40,457 $ 10,895 December 31, 2015 Level 1 Level 2 Level 3 Assets: Intangible assets $ - $ - $ 33,667 Goodwill - - 21,166 Total assets $ - $ - $ 54,833

Description of Business and B44

Description of Business and Basis of Presentation (Details Textual) $ in Millions	Oct. 05, 2016USD ($)
Soluble Systems, LLC [Member]
Proceeds from Issuance of Common Stock And Debt	$ 45

Summary of Significant Accoun45

Summary of Significant Accounting Policies (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Balance	$ 21,166	$ 4,100
Goodwill	0	17,066	[1]
Impairment loss	(9,207)
Balance	$ 11,959	$ 21,166
[1]	Goodwill acquired as a result of the acquisition of Celleration in May 2015. See Note 5 – Acquisitions for further information on the acquisition.

Summary of Significant Accoun46

Summary of Significant Accounting Policies (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Summary Of Significant Account Policies [Line Items]
Goodwill	$ 11,959,000		$ 21,166,000	$ 4,100,000
Research and Development Expense, Total	859,000	$ 715,000	715,000
Advertising Expense	2,400,000		2,100,000
Allowance for Doubtful Accounts Receivable	213,000		175,000
Total Impairments, Goodwill	9,207,000
Impairment of in process research and development	1,688,000		0
Impairment charges	$ 10,895,000		$ 0

Going Concern (Details Textual)

Going Concern (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015	Dec. 31, 2014
Net Income (Loss) Attributable to Parent, Total	$ (28,243)		$ (26,017)
Net Cash Provided by (Used in) Operating Activities, Continuing Operations, Total	(18,335)		(21,622)
Retained Earnings (Accumulated Deficit), Total	(124,303)		(96,060)
Cash and Cash Equivalents, at Carrying Value, Total	5,580		$ 26,080	$ 16,771
Intangible Assets, Net (Including Goodwill)	40,500
Gross Revenue	$ 24,600	$ 22,250

Net Loss Per Common Share (Deta

Net Loss Per Common Share (Details) - shares	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	12,034,921	10,294,824
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	7,199,286	6,230,549
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	3,365,407	3,372,550
Non-vested Restricted Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	1,470,228	691,725

Acquisitions (Details)

Acquisitions (Details) - USD ($) $ in Thousands	1 Months Ended	12 Months Ended
	May 29, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Consideration:
Common stock		$ 0	$ 15,208
Cash paid		2,573	0
Fair value of contingent consideration		0	15,570
Goodwill		$ 11,959	$ 21,166	$ 4,100
Acquisition of Celleration, Inc [Member]
Consideration:
Common stock	$ 15,208
Cash paid	15,476
Fair value of contingent consideration	15,570
Total consideration	46,254
Cash	528
Trade receivables	877
Inventory	341
Other current assets	207
Improvements and equipment	411
Goodwill	17,066
Accounts payable	(308)
Accrued expenses and other liabilities	(1,698)
Deferred tax liability	(3,122)
Net assets acquired	46,254
Acquisition of Celleration, Inc [Member] | Trade Names [Member]
Consideration:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	3,601
Acquisition of Celleration, Inc [Member] | Technology [Member]
Consideration:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	27,143
Acquisition of Celleration, Inc [Member] | Customer Relationships [Member]
Consideration:
Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill	$ 1,208

Acquisitions (Details 1)

Acquisitions (Details 1) - Acquisition of Celleration, Inc [Member] $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015USD ($)$ / shares
Business Acquisition [Line Items]
Revenues	$ 16,266
Net loss	$ (31,877)
Net loss per share | $ / shares	$ (1.31)

Acquisitions (Details Textual)

Acquisitions (Details Textual) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended	12 Months Ended
	Mar. 31, 2016	May 29, 2015	Sep. 30, 2016	Dec. 31, 2016		Dec. 31, 2015
Business Acquisition [Line Items]
Revenues, Total				$ 18,240		$ 12,177
Working Capital		$ 300
Business Combination, Contingent Consideration, at Fair Value				0		15,570
Payments to Acquire Businesses, Gross				2,573		0
Business Combination, Contingent Consideration, Liability, Noncurrent				1,141		$ 14,455
Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability Due To Accretion			$ 9,500
Continget Consideration Installment Two [Member]
Business Acquisition [Line Items]
Business Combination, Contingent Consideration, Liability, Noncurrent				$ 1,400
MIST Therapy [Member]
Business Acquisition [Line Items]
Business Combination Agreed Contingent Consideration Payable Ratio In Excess Of Certain Revenue Targets				3.5		3.5
2015 MIST Therapy
Business Acquisition [Line Items]
Revenues, Total				$ 10,200
2014 MIST Therapy
Business Acquisition [Line Items]
Revenues, Total				$ 8,700
Common Stock [Member]
Business Acquisition [Line Items]
Stock Issued During Period, Shares, Acquisitions				985,936	[1]	3,168,229
Acquisition of Celleration, Inc [Member]
Business Acquisition [Line Items]
Business Acquisition Initial Cash Payment		15,500
Business Combination, Contingent Consideration, at Fair Value		15,570
Business Combination, Consideration Transferred		46,254
Payments to Acquire Businesses, Gross		$ 15,476
Acquisition of Celleration, Inc [Member] | Installment One [Member]
Business Acquisition [Line Items]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares	986,000
Payments to Acquire Businesses, Gross	$ 2,600
Fair Value Inputs, Discount Rate				12.50%
Business Acquisition, Equity Interest Issued or Issuable, Value Assigned	$ 2,600
Acquisition of Celleration, Inc [Member] | Common Stock [Member]
Business Acquisition [Line Items]
Stock Issued During Period, Shares, Acquisitions		3,168,229
[1]	Includes $2.6 million that was part of contingent consideration as of December 31, 2015, which was credited to equity upon the issuance of 985,936 common shares during the year ended December 31, 2016.

Discontinued Operations (Detail

Discontinued Operations (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Proceeds from sale
Consideration for inventory	$ 603
Consideration for intangible assets	3,500
Total Consideration	4,103
Less: Net book value of assets sold to BSN
Inventory, net	(603)
Intangibles, net	(189)
Total net book value of assets	(792)
Gain on sale of assets	$ 3,311	$ 0

Discontinued Operations (Deta53

Discontinued Operations (Details 1) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Revenue, net of returns, allowances and discounts	$ 1,709	$ 2,864
Cost of revenues	536	823
Gross profit	1,173	2,041
Selling, general and administrative	323	841
Income from discontinued operations, net of tax	$ 850	$ 1,200

Discontinued Operations (Deta54

Discontinued Operations (Details 2) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable, net		$ 457
Inventory, net		858
Total current assets	$ 0	1,315
Intangible assets, net		227
Total assets		1,542
Accounts payable		44
Accrued expenses and other current liabilities		59
Total current liabilities	$ 0	$ 103

Discontinued Operations (Deta55

Discontinued Operations (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Proceeds from Divestiture of Businesses and Interests in Affiliates	$ 3,500,000
Contractual Obligation	900,000
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax	3,311,000	$ 0
Discontinued Operation, Tax Effect of Gain (Loss) from Disposal of Discontinued Operation	0	0
Sales Revenue, Services, Other	100,000
Amortization of Intangible Assets	3,500,000	2,400,000
Purchase Agreement [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax	3,300,000
Selling, General and Administrative Expenses [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Amortization of Intangible Assets	$ 38,000	$ 76,000

Note Receivable (Details Textua

Note Receivable (Details Textual) - USD ($)	Dec. 31, 2016	Oct. 05, 2016	Aug. 25, 2016
Debt Instrument, Face Amount		$ 1,000,000
Cash Advance		500,000
Prepaid Expenses and Other Current Assets [Member]
Notes, Loans and Financing Receivable, Net, Current	$ 0
Bridge Loan [Member]
Debt Instrument, Face Amount		$ 1,000,000	$ 500,000
Debt Instrument, Interest Rate, Stated Percentage			6.00%

Inventory (Details)

Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Inventory [Line Items]
Raw materials	$ 135	$ 241
Work in process	173	228
Finished goods	2,394	1,865
Less: Inventory reserve for excess and slow moving inventory	0	(59)
Total	$ 2,702	$ 2,275

Improvements and Equipment, n58

Improvements and Equipment, net (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Machinery and equipment		$ 5,041	$ 3,621
Office furniture and equipment		337	88
Leasehold improvements	[1]	595	253
Property, Plant and Equipment, Gross, Total		5,973	3,962
Less: Accumulated depreciation and amortization		(3,881)	(2,115)
Improvements and equipment, net		$ 2,092	$ 1,847
Machinery and Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life		3 years
Machinery and Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life		10 years
Office Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life		3 years
Office Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, Plant and Equipment, Useful Life		10 years
[1]	Leasehold improvements are amortized over the shorter of the remaining lease term or estimated useful life.

Improvements and Equipment, n59

Improvements and Equipment, net (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Property, Plant and Equipment [Line Items]
Depreciation, Depletion and Amortization, Total	$ 1,800,000	$ 421,000

Intangible Assets (Details)

Intangible Assets (Details) - USD ($) $ in Thousands		1 Months Ended	3 Months Ended	12 Months Ended
		Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2016		Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Gross Amount						$ 38,443
Accumulated Amortization						(4,776)
Impairment				$ (1,688)		0
Net Carrying Amount		$ 28,498	$ 28,498	28,498		33,667
Indefinite-lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount						3,601
Accumulated Amortization						0
Impairment						0
Net Carrying Amount						3,601
Intangible assets subject to amortization [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount		38,443	38,443	38,443		34,842
Accumulated Amortization		(8,257)	(8,257)	(8,257)		(4,776)
Impairment				(1,688)		0
Net Carrying Amount		28,498	28,498	$ 28,498		$ 30,066
Technology [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)				10 years		10 years
Gross Amount		32,539	32,539	$ 32,539		$ 32,539
Accumulated Amortization		(7,312)	(7,312)	(7,312)		(4,057)
Impairment				0		0
Net Carrying Amount		25,227	25,227	25,227		28,482
Customer relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount		1,984	1,984	1,984		1,984
Accumulated Amortization		(639)	(639)	(639)		(449)
Impairment				0		0
Net Carrying Amount		1,345	1,345	$ 1,345		$ 1,535
Customer relationships [Member] | Minimum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)				9 years		9 years
Customer relationships [Member] | Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)				12 years		12 years
Tradename [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)				3 years		3 years
Gross Amount		111	111	$ 111		$ 111
Accumulated Amortization		(98)	(98)	(98)		(62)
Impairment				0		0
Net Carrying Amount		$ 13	13	$ 13		49
MIST Therapy Trade Name [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)		1 year 6 months		3 years	[1]
Gross Amount	[1]	$ 3,601	3,601	$ 3,601
Accumulated Amortization	[1]	0	0	0
Impairment			(1,700)	(1,688)	[1]
Net Carrying Amount	[1]	1,913	1,913	$ 1,913
MIST Therapy Trade Name [Member] | Indefinite-lived Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Amount	[1]					3,601
Accumulated Amortization	[1]					0
Impairment	[1]					0
Net Carrying Amount	[1]					$ 3,601
Non-compete [Member]
Finite-Lived Intangible Assets [Line Items]
Useful Life (Years)				1 year		1 year
Gross Amount		208	208	$ 208		$ 208
Accumulated Amortization		(208)	(208)	(208)		(208)
Impairment				0		0
Net Carrying Amount		$ 0	$ 0	$ 0		$ 0
[1]	In December 2016, the Company determined the tradename related to MIST Therapy was no longer an indefinite-lived intangible asset. The Company assigned a remaining useful of approximately 1.5 years, consistent with the Company’s other trademarks.

Intangible Assets (Details 1)

Intangible Assets (Details 1) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
2,017	$ 4,807
2,018	4,007
2,019	3,169
2,020	3,144
2,021	3,098
Thereafter	10,273
Total	$ 28,498	$ 33,667

Intangible Assets (Details Text

Intangible Assets (Details Textual) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2016	Dec. 31, 2016		Dec. 31, 2015
Finite-Lived Intangible Assets [Line Items]
Amortization of Intangible Assets			$ 3,500		$ 2,400
Impairment of in process research and development			$ 1,688		$ 0
MIST Therapy Trade Name [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Asset, Useful Life	1 year 6 months		3 years	[1]
Impairment of in process research and development		$ 1,700	$ 1,688	[1]
[1]	In December 2016, the Company determined the tradename related to MIST Therapy was no longer an indefinite-lived intangible asset. The Company assigned a remaining useful of approximately 1.5 years, consistent with the Company’s other trademarks.

Accrued Expenses (Details)

Accrued Expenses (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Accrued Liabilities Current Line Items [Line Items]
Salaries, benefits and incentive compensation	$ 3,070	$ 2,118
Milestone payment to licensor	1,000	0
Professional fees	692	671
Royalty fees	197	52
Deferred revenue	181	92
Other	146	138
Total accrued expenses and other current liabilities	$ 5,286	$ 3,071

Operating Leases (Details)

Operating Leases (Details) $ in Thousands	Dec. 31, 2016USD ($)
Operating Leased Assets [Line Items]
2,017	$ 500
2,018	506
2,019	512
2,020	519
2,021	525
Thereafter	1,311
Total	$ 3,873

Operating Leases (Details Textu

Operating Leases (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense	$ 267,000	$ 0
Operating Leases [Member]
Operating Leased Assets [Line Items]
Operating Leases, Rent Expense	542,000	$ 282,000
Accrued And Other Long Term Liabilities [Member]
Operating Leased Assets [Line Items]
Incentive from Lessor	$ 267,000

Debt (Details)

Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Debt Instrument [Line Items]
Long-term debt	$ 13,752	$ 15,500
Unamortized debt issuance and discount costs	(2,211)	(3,374)
Total	$ 11,541	$ 12,126

Debt (Details Textual)

Debt (Details Textual) - USD ($)	6 Months Ended	12 Months Ended
	Jun. 30, 2016	Dec. 31, 2016	Sep. 30, 2016	Dec. 31, 2015	Jan. 26, 2017	Oct. 05, 2016	May 29, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Debt Instrument, Face Amount						$ 1,000,000
Common Stock, Par or Stated Value Per Share		$ 0.001		$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 5.5138
Derivative Liability		$ 20,000		$ 861,000				$ 304,000
Amortization of Debt Discount (Premium)		$ 841,000		565,000
Warrant Expiration Period		five-year warrant
Common Stock Purchased By Warrants Issued		750,000
Proceeds from Divestiture of Businesses and Interests in Affiliates		$ 3,500,000
Exit fee payment, Credit Agreement Description		The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 2% of the outstanding principal balance immediately prior to the final payment or $200,000, which was amended in conjunction with the extinguishment of debt described below from the greater of 1% of the outstanding principal balance immediately prior to the final payment or $100,000.
Gain (Loss) on Extinguishment of Debt		$ (373,000)		0
Revenues, Total		18,240,000		12,177,000
Long-term Debt, Gross		13,752,000		15,500,000
Subsequent Event [Member]
Debt Instrument [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights					2,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights					$ 0.50
Fair Value, Inputs, Level 3 [Member]
Debt Instrument [Line Items]
Derivative Liability		20,000		861,000
Warrant [Member] | Fair Value, Inputs, Level 3 [Member]
Debt Instrument [Line Items]
Derivative Liability		2,700,000
Interest Expense [Member]
Debt Instrument [Line Items]
Amortization of Financing Costs		273,000		169,000
Amortization of Debt Discount (Premium)		569,000		$ 397,000
Senior Secured Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount							$ 15,500,000
Debt Issuance Costs1		1,300,000
Amortization of Debt Discount (Premium)		$ 226,000
Debt Instrument, Interest Rate Terms		accrues interest at an annual rate equal to the greater of (a) one-month LIBOR or 1% plus (b) 9.75%
Debt Instrument, Term		4 years
Debt Instrument, Payment Terms		is interest only for the first 24 months, followed by monthly amortization payments of $225,000, with the remaining unpaid balance due on the maturity date
Debt Instrument, Maturity Date, Description		The Company is required to pay an exit fee when the term loan is paid in full equal to the greater of 2% of the outstanding principal balance immediately prior to the final payment or $200,000
Debt Instrument, Interest Rate During Period		10.75%
Payments for Prepayment Penalties	$ 52,000
Proceeds from Divestiture of Businesses and Interests in Affiliates	1,800,000
Repayments of Debt	$ 1,700,000
Gain (Loss) on Extinguishment of Debt		$ 373,000
Prepayment Penalty On Early Extinguishment Of Debt		52,000
Write off of Deferred Debt Issuance Cost		95,000
Long-term Debt, Gross		13,800,000
Credit Agreement [Member]
Debt Instrument [Line Items]
Revenues, Total		$ 24,000,000	$ 22,300,000

Commitments and Contingencies (

Commitments and Contingencies (Details Textual) - USD ($)	Jul. 15, 2011	Dec. 31, 2016	Dec. 31, 2015
Commitments And Contingencies [Line Items]
Accrued Liabilities, Current		$ 5,286,000	$ 3,071,000
Accounts Payable, Current		2,612,000	2,594,000
AIQA Cedar Inc [Member]
Commitments And Contingencies [Line Items]
Accounts Payable, Current		598,000	497,000
Alliqua Biomedical Subsidiary [Member]
Commitments And Contingencies [Line Items]
Contractual Obligation, Due in Next Twelve Months		600,000
Royalty Expense		600,000	500,000
Human Longevity, Inc [Member]
Commitments And Contingencies [Line Items]
Royalty Expense		493,000	229,000
Accrued Liabilities, Current		197,000	$ 52,000
Revenue Recognition, Milestone Method, Milestone Expenses		1,000,000
Human Longevity, Inc [Member] | First Commercial Sale [Member]
Commitments And Contingencies [Line Items]
Contractual Obligation, Due in Next Twelve Months		500,000
Human Longevity, Inc [Member] | Second Commercial Sale [Member]
Commitments And Contingencies [Line Items]
Contractual Obligation, Due in Next Twelve Months		$ 500,000
Noble Fiber Technologies License Agreement [Member]
Commitments And Contingencies [Line Items]
Royalty Fee Percentage	9.75%

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016		Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares Issued	1,025		720
Grant Date Value	$ 1,076		$ 4,368
Employee One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date	Feb. 9, 2016		Feb. 6, 2015
Shares Issued	325		600
Vesting Term	0	[1]	0	[2]
Grant Date Value	$ 474		$ 3,738
Employee Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Issuance Date	May 11, 2016		Jun. 15, 2015
Shares Issued	700		120
Vesting Term	0	[3]	0	[4]
Grant Date Value	$ 602		$ 630
[1]	Vests on the earlier of (a) the first anniversary of the date of grant or (b) the participant’s termination of service by the Company without cause.
[2]	Vests in three equal annual installments, with one-third vesting on each of February 6, 2016, February 6, 2017 and February 6, 2018.
[3]	Vests pursuant to the satisfaction of certain performance conditions.
[4]	Vests in equal quarterly installments, with one-fourth vesting immediately and the remaining vesting equally over the next 3 years on the anniversaries of the date of grant.

Stockholders' Equity (Details 1

Stockholders' Equity (Details 1) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Granted (in shares)	1,025	720
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Shares, Non-vested, December 31 (in shares)	692	188
Number of Shares, Granted (in shares)	1,025	720
Number of Shares, Vested (in shares)	(238)	(216)
Number of Shares, Forfeited (in shares)	(8)	0
Number of Shares, Non-vested, December 31 (in shares)	1,471	692
Weighted Average Grant Date Fair Value, Non-vested, December 31 (in dollars per share)	$ 6.11	$ 7.03
Weighted Average Grant Date Fair Value, Granted (in dollars per share)	1.05	6.07
Weighted Average Grant Date Fair Value, Vested (in dollars per share)	6	6.76
Weighted Average Grant Date Fair Value, Forfeited (in dollars per share)	1.46	0
Weighted Average Grant Date Fair Value, Non-vested, December 31 (in dollars per share)	$ 2.43	$ 6.11
Total Grant Date Fair Value, Non-vested, December 31	$ 4,226	$ 1,322
Total Grant Date Fair Value, Granted	1,076	4,368
Total Grant Date Fair Value, Vested	(1,428)	(1,464)
Total Grant Date Fair Value, Forfeited	(12)	0
Total Grant Date Fair Value, Non-vested, December 31	$ 3,862	$ 4,226

Stockholders' Equity (Details 2

Stockholders' Equity (Details 2) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Warrants, Issued (in shares)	1,025	720
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding at Beginning of the period (in shares)	3,373	2,675
Number of Warrants, Issued (in shares)	0	750
Number of Warrants, Exercised (in shares)	0	(16)
Number of Warrants, Cancelled (in shares)	(7)	(36)
Number of Options, Outstanding at End of the period (in shares)	3,366	3,373
Number of Warrants, Exercisable, December 31, 2016 (in shares)	3,366
Weighted Average Exercise Price, Outstanding, Beginning of the period, (in dollars per share)	$ 5.70	$ 5.76
Weighted Average Exercise Price, Issued (in dollars per share)	0	5.51
Weighted Average Exercise Price, Exercised (in dollars per share)	0	2.19
Weighted Average Exercise Price, Cancelled (in dollars per share)	8.75	7.88
Weighted Average Exercise Price, Outstanding, End of the period, (in dollars per share)	5.69	$ 5.70
Weighted Average Exercise Price, Exercisable December 31, 2016 (in dollars per share)	$ 5.69
Weighted Average Remaining Life In Years, Outstanding, December 31, 2016 (Years)	2 years 1 month 6 days
Weighted Average Remaining Life In Years, Exercisable, December 31, 2016 (Years)	2 years 1 month 6 days
Intrinsic Value, Outstanding, December 31, 2016	$ 0
Intrinsic Value, Exercisable, December 31, 2016	$ 0

Stockholders' Equity (Details 3

Stockholders' Equity (Details 3) shares in Thousands	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	3,366
Warrants Exercisable, Average Remaining Life In Years	2 years 1 month 6 days
Warrants Exercisable, Number of Warrants	3,366
Exercise Price Ranage 2.19 - 2.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	93
Warrants Exercisable, Average Remaining Life In Years	9 months 18 days
Warrants Exercisable, Number of Warrants	93
Exercise Price Ranage 2.19 - 2.99 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 2.19
Exercise Price Ranage 2.19 - 2.99 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 2.99
Exercise Price Ranage 3.00 - 3.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	77
Warrants Exercisable, Average Remaining Life In Years	1 month 6 days
Warrants Exercisable, Number of Warrants	77
Exercise Price Ranage 3.00 - 3.99 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 3
Exercise Price Ranage 3.00 - 3.99 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 3.99
Exercise Price Range 4.00 - 4.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	977
Warrants Exercisable, Average Remaining Life In Years	1 year 6 months
Warrants Exercisable, Number of Warrants	977
Exercise Price Range 4.00 - 4.99 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 4
Exercise Price Range 4.00 - 4.99 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 4.99
Exercise Price Range 5.00 - 5.99 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	1,791
Warrants Exercisable, Average Remaining Life In Years	2 years 6 months
Warrants Exercisable, Number of Warrants	1,791
Exercise Price Range 5.00 - 5.99 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 5
Exercise Price Range 5.00 - 5.99 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 5.99
Exercise Price Range 6.00 - 10.50 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Number of Warrants	428
Warrants Exercisable, Average Remaining Life In Years	2 years 3 months 18 days
Warrants Exercisable, Number of Warrants	428
Exercise Price Range 6.00 - 10.50 [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 6
Exercise Price Range 6.00 - 10.50 [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants Outstanding, Exercise Price | $ / shares	$ 10.50

Stockholders' Equity (Details 4

Stockholders' Equity (Details 4)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected dividends	0.00%	0.00%
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	1.14%	1.19%
Expected term (years)	5 years 14 days	5 years
Expected volatility	89.53%	93.70%
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk free interest rate	2.06%	2.11%
Expected term (years)	6 years 6 months	6 years 6 months
Expected volatility	89.95%	98.25%

Stockholders' Equity (Details 5

Stockholders' Equity (Details 5) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Granted (in shares)	1,025	720
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of Options, Outstanding at Beginning of the period (in shares)	6,231	4,818
Number of Options, Granted (in shares)	1,649	1,905
Number of Options, Exercised (in shares)	0	(76)
Number of Options, Forfeited (in shares)	(680)	(416)
Number of Options, Outstanding at End of the period (in shares)	7,200	6,231
Number of Options, Exercisable, December 31, 2016 (in shares)	4,205
Weighted Average Exercise Price, Outstanding, Beginning of the period, (in dollars per share)	$ 6.26	$ 6.56
Weighted Average Exercise Price, Granted (in dollars per share)	1.05	5.38
Weighted Average Exercise Price, Exercised (in dollars per share)	0	4.38
Weighted Average Exercise Price, Forfeited (in dollars per share)	3.95	5.96
Weighted Average Exercise Price, Outstanding, End of the period, (in dollars per share)	5.29	$ 6.26
Weighted Average Exercise Price, Exercisable December 31, 2016 (in dollars per share)	$ 6.06
Weighted Average Remaining Life In Years, Outstanding, December 31, 2016 (Years)	7 years 1 month 6 days	0 years
Weighted Average Remaining Life In Years, Exercisable, Exercisable, December 31, 2016 (Years)	6 years 3 months 18 days
Intrinsic Value, Outstanding, December 31, 2016	$ 0
Intrinsic Value, Exercisable, December 31, 2016	$ 0

Stockholders' Equity (Details 6

Stockholders' Equity (Details 6) shares in Thousands	12 Months Ended
	Dec. 31, 2016$ / sharesshares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Outstanding Number of Options (in shares) | shares	3,366
Options Exercisable, Exercisable Number of Options (in shares) | shares	3,366
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Outstanding Number of Options (in shares) | shares	7,200
Options Exercisable, Weighted Average Remaining Life in Years (in years)	6 years 3 months 18 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	4,205
Exercise Price Range 0.80 - 0.99 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 0.80
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	0.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 0.87
Options Outstanding, Outstanding Number of Options (in shares) | shares	313
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 0.86
Options Exercisable, Weighted Average Remaining Life in Years (in years)	9 years 4 months 24 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	131
Exercise Price Range 1.00 - 1.99 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 1
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	1.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 1.07
Options Outstanding, Outstanding Number of Options (in shares) | shares	1,159
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 0
Options Exercisable, Weighted Average Remaining Life in Years (in years)	0 years
Options Exercisable, Exercisable Number of Options (in shares) | shares	0
Exercise Price Range 2.00 - 2.99 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 2
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	2.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 2.24
Options Outstanding, Outstanding Number of Options (in shares) | shares	25
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 2.38
Options Exercisable, Weighted Average Remaining Life in Years (in years)	8 years 10 months 24 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	2
Exercise Price Range 3.00 - 3.99 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 3
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	3.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 3.36
Options Outstanding, Outstanding Number of Options (in shares) | shares	501
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 3.36
Options Exercisable, Weighted Average Remaining Life in Years (in years)	6 years 6 months
Options Exercisable, Exercisable Number of Options (in shares) | shares	442
Exercise Price Range 4.00 - 4.99 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 4
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	4.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 4.60
Options Outstanding, Outstanding Number of Options (in shares) | shares	1,072
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 4.52
Options Exercisable, Weighted Average Remaining Life in Years (in years)	5 years 3 months 18 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	792
Exercise Price Range 5.00 - 5.99 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 5
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	5.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 5.29
Options Outstanding, Outstanding Number of Options (in shares) | shares	625
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 5.35
Options Exercisable, Weighted Average Remaining Life in Years (in years)	6 years 1 month 6 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	372
Exercise Price Range 6.00 - 6.99 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 6
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	6.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 6.60
Options Outstanding, Outstanding Number of Options (in shares) | shares	2,177
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 6.68
Options Exercisable, Weighted Average Remaining Life in Years (in years)	6 years 9 months 18 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	1,650
Exercise Price Range 7.00 - 7.99 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 7
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	7.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 7.75
Options Outstanding, Outstanding Number of Options (in shares) | shares	31
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 7.75
Options Exercisable, Weighted Average Remaining Life in Years (in years)	7 years 3 months 18 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	21
Exercise Price Range 8.00 - 8.99 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 8
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	8.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 8.74
Options Outstanding, Outstanding Number of Options (in shares) | shares	780
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 8.74
Options Exercisable, Weighted Average Remaining Life in Years (in years)	5 years 8 months 12 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	556
Exercise Price Range 9.00 - 9.99 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 9
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	9.99
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 9
Options Outstanding, Outstanding Number of Options (in shares) | shares	253
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 9
Options Exercisable, Weighted Average Remaining Life in Years (in years)	6 years 2 months 12 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	183
Exercise Price Range 10.00 - 26.69 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options Outstanding, Exercise Price, Lower Range Limit (in dollars per share)	$ 10
Options Outstanding, Exercise Price, Upper Range Limit (in dollars per share)	26.69
Options Outstanding Weighted Average Exercise Price (in dollars per share)	$ 10.96
Options Outstanding, Outstanding Number of Options (in shares) | shares	264
Options Exercisable Weighted Average Exercise Price (in dollars per share)	$ 11.01
Options Exercisable, Weighted Average Remaining Life in Years (in years)	6 years 2 months 12 days
Options Exercisable, Exercisable Number of Options (in shares) | shares	56

Stockholders' Equity (Details T

Stockholders' Equity (Details Textual) - USD ($)	May 04, 2015	Dec. 31, 2016	Dec. 31, 2015	May 06, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense		$ 4,900,000	$ 8,600,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		1,025,000	720,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 1,076,000	$ 4,368,000
Proceeds from Issuance of Common Stock	$ 32,200,000	$ 0	$ 32,197,000
Preferred Stock, Shares Authorized		1,000,000	1,000,000
Preferred Stock, Par or Stated Value Per Share		$ 0.001	$ 0.001
Common Stock, Shares Authorized		95,000,000	95,000,000	45,714,286
Cost of Sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense		$ 200,000	$ 300,000
Selling, General and Administrative Expenses [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense		$ 4,700,000	$ 8,300,000
Plan 2011 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		1,828,571
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		214,617
Plan 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized		5,500,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		609,856
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized		3,500,000
Plan 2014 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value		$ 1,300,000
Minimum [Member] | Plan 2014 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 0.80
Maximum [Member] | Plan 2014 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 2.20
Vesting Year One [Member] | Plan 2014 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		225,000
Vesting Year Two [Member] | Plan 2014 [Member] | Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		1,424,000
Common Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock Issued During Period, Shares, New Issues	7,582,418		7,582,418
Sale of Stock, Price Per Share	$ 4.55
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total		$ 3,100,000
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition		1 year 3 months 18 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		1,025,000	720,000
Warrant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Warrants To Purchase Common Stock			9,142
Stock Issued During Period Shares Warrants Exercised			8,970
Number Of Warrants To Purchase Common Stock Exercised			15,999
Warrants Exercised, Intrinsic Value			$ 45,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		0	750,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 0	$ 5.51
Investment Warrants, Exercise Price			$ 2.19

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Federal:
Current	$ 0	$ 0
Deferred	(627)	(1,509)
State and local:
Current	4	3
Deferred	(92)	(212)
Income tax provision	$ (715)	$ (1,718)

Income Taxes (Details 1)

Income Taxes (Details 1)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Line Items]
U.S. federal statutory rate	34.00%	34.00%
State tax rate, net of federal benefit	4.50%	4.80%
Permanent differences
- Change in fair value of warrant liability	0.90%	2.50%
- Change in fair value of contingent consideration	10.40%	1.70%
-Acquisition costs	0.00%	(2.10%)
-Intangible impairment	(9.30%)	0.00%
- Other	(0.40%)	(0.60%)
Adjustments to deferred taxes	(8.20%)	(2.30%)
Change in valuation allowance	(29.70%)	(32.10%)
Income tax provision	2.20%	5.90%

Income Taxes (Details 2)

Income Taxes (Details 2) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015
Deferred tax assets:
Net operating loss carryforwards	$ 40,117	$ 35,284
Stock-based compensation	8,671	7,713
Accruals	541	496
Transaction costs	732	0
Other	861	253
Total deferred tax assets	50,922	43,746
Valuation allowance	(41,482)	(32,977)
Deferred tax assets, net of valuation allowance	9,440	10,769
Deferred tax liabilities:
Property and equipment	(281)	(409)
Intangible assets	(9,159)	(10,360)
Goodwill	(749)	(1,468)
Total deferred tax liabilities	(10,189)	(12,237)
Net deferred tax liabilities	$ (749)	$ (1,468)

Income Taxes (Details Textual)

Income Taxes (Details Textual) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Income Taxes [Line Items]
Operating Loss Carryforwards Expiration Year	2020 and through 2036
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount	$ 8.5	$ 8.9
Increase (Decrease) In Net Operating Loss Carryforwards	4.8
Acquisition of Celleration, Inc [Member]
Income Taxes [Line Items]
Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount		1.7
Domestic Tax Authority [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	104.9	93
Domestic Tax Authority [Member] | Acquisition of Celleration, Inc [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	47.9
Domestic Tax Authority [Member] | Choice Therapeutics, Inc. [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	2.5	2.5
State and Local Jurisdiction [Member] | Pennsylvania [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	24.6	22.9
State and Local Jurisdiction [Member] | Florida [Member]
Income Taxes [Line Items]
Operating Loss Carryforwards	$ 10.9	$ 9.8

Related Party (Details Textual)

Related Party (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Related Party Transaction [Line Items]
Related Party Transaction, Expenses from Transactions with Related Party	$ 491,000	$ 5,000
Accounts Payable, Related Parties	$ 102,000	$ 5,000

Concentration of Risk (Details

Concentration of Risk (Details Textual)	12 Months Ended
	Dec. 31, 2015
Customer [Member] | Sales Revenue, Net [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	10.00%

Fair Value Measurement (Details

Fair Value Measurement (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	$ 861	$ 304
Initial fair value of contingent consideration	0	15,570
Value of warrants issued	0	2,683
Value of warrants exercised	0	(31)
Change in fair value	(841)	(2,095)
Ending balance	20	861
Contingent Consideration [Member]
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Beginning balance	17,028	2,932
Initial fair value of contingent consideration	0	15,570
Payments of contingent consideration	(5,147)	0
Change in fair value	(10,065)	(1,474)
Ending balance	$ 1,816	$ 17,028

Fair Value Measurement (Detai84

Fair Value Measurement (Details 1) - USD ($) $ in Thousands	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Liabilities:
Warrant liabilities	$ 20	$ 861	$ 304
Contingent consideration		2,600
Fair Value, Inputs, Level 1 [Member]
Liabilities:
Warrant liabilities	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 2 [Member]
Liabilities:
Warrant liabilities	0	0
Contingent consideration	0	0
Total liabilities	0	0
Fair Value, Inputs, Level 3 [Member]
Liabilities:
Warrant liabilities	20	861
Contingent consideration	1,816	17,028
Total liabilities	$ 1,836	$ 17,889

Fair Value Measurement (Detai85

Fair Value Measurement (Details 2) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Assets:
Impairment of in process research and development	$ 1,688	$ 0
Total Impairments, Goodwill	9,207
Impairment charges	10,895	0
Fair Value, Inputs, Level 1 [Member]
Assets:
Intangible assets	0	0
Goodwill	0	0
Total assets	0	0
Fair Value, Inputs, Level 2 [Member]
Assets:
Intangible assets	0	0
Goodwill	0	0
Total assets	0	0
Fair Value, Inputs, Level 3 [Member]
Assets:
Intangible assets	28,498	33,667
Goodwill	11,959	21,166
Total assets	$ 40,457	$ 54,833

Fair Value Measurement (Detai86

Fair Value Measurement (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)	$ 841,000	$ 4,000
Derivative Liability	$ 20,000	861,000	$ 304,000
Class of Warrant or Right, Exercise Price of Warrants or Rights	$ 5.5138
Common Stock Purchased By Warrants Issued	750,000
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements	$ 0	31,000
Asset Impairment Charges	10,895,000	$ 0
Common Stock [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrants To Purchase Common Stock		9,142
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements		$ 31,000
Credit Agreement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 5.5138
Common Stock Purchased By Warrants Issued		750,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate		98.25%
Fair Value Assumptions, Risk Free Interest Rate		0.96%
Fair Value Assumptions, Expected Term		2 years 6 months 7 days
Fair Value Assumptions, Expected Dividend Rate		0.00%
Fair Value, Liabilities Measured on Recurring Basis, Change in Unrealized Gain (Loss)		$ 2,100,000
Derivative Liability	$ 20,000	$ 861,000
Fair Value, Inputs, Level 3 [Member] | Credit Agreement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate		98.25%
Fair Value Assumptions, Risk Free Interest Rate		1.49%
Fair Value Assumptions, Expected Term		5 years
Fair Value Assumptions, Expected Dividend Rate		0.00%
Derivative Liability		$ 2,700,000
Fair Value, Inputs, Level 3 [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate		89.95%
Fair Value Assumptions, Expected Dividend Rate	0.00%	0.00%
Warrants To Purchase Common Stock	816,287	816,287
Fair Value, Inputs, Level 3 [Member] | Maximum [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate	72.16%
Fair Value Assumptions, Risk Free Interest Rate	1.47%	1.54%
Fair Value Assumptions, Expected Term	3 years 4 months 28 days	4 years 4 months 28 days
Fair Value, Inputs, Level 3 [Member] | Minimum [Member] | Warrant Liability [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Fair Value Assumptions, Expected Volatility Rate	65.74%
Fair Value Assumptions, Risk Free Interest Rate	0.85%	1.06%
Fair Value Assumptions, Expected Term	10 months 10 days	1 year 10 months 10 days

Defined Contribution Plan (Deta

Defined Contribution Plan (Details Textual) - USD ($)	12 Months Ended
	Dec. 31, 2016	Dec. 31, 2015
Defined Benefit Plan Disclosure [Line Items]
Description of Defined Contribution Pension and Other Postretirement Plans	Participants may contribute up to 100% of their total compensation to the Plan, not to exceed the limit as defined in the Code.
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	50.00%
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent	6.00%
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 105,000	$ 75,000

Subsequent Events (Details Text

Subsequent Events (Details Textual) - USD ($)	1 Months Ended
	Feb. 27, 2017	Jan. 31, 2017	Jan. 26, 2017	Dec. 31, 2016	Oct. 05, 2016	Aug. 25, 2016	Dec. 31, 2015
Subsequent Event [Line Items]
Debt Instrument, Face Amount					$ 1,000,000
Long-term Debt, Gross				$ 13,752,000			$ 15,500,000
Common Stock, Par or Stated Value Per Share				$ 0.001			$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights				$ 5.5138
Credit Agreement [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights							$ 5.5138
Bridge Loan [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount					$ 1,000,000	$ 500,000
Debt Instrument, Interest Rate, Stated Percentage						6.00%
Subsequent Event [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			2,000,000
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.50
Subsequent Event [Member] | Private Placement [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	5,540,000
Share Price	$ 0.50
Proceeds from Issuance of Private Placement	$ 2,770,000
Subsequent Event [Member] | Credit Agreement [Member]
Subsequent Event [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights			2,000,000
Common Stock, Par or Stated Value Per Share			$ 0.001
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 0.50
Subsequent Event [Member] | Bridge Loan [Member]
Subsequent Event [Line Items]
Debt Instrument, Face Amount		$ 350,000
Debt Instrument, Interest Rate, Stated Percentage		6.00%
Long-term Debt, Gross		$ 1,400,000